1
|
Perez B, Aljumaily R, Marron TU, Shafique MR, Burris H, Iams WT, Chmura SJ, Luke JJ, Edenfield W, Sohal D, Liao X, Boesler C, Machl A, Seebeck J, Becker A, Guenther B, Rodriguez-Gutierrez A, Antonia SJ. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors. ESMO Open 2024; 9:102217. [PMID: 38320431 PMCID: PMC10937199 DOI: 10.1016/j.esmoop.2023.102217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/30/2023] [Accepted: 12/07/2023] [Indexed: 02/08/2024] Open
Abstract
INTRODUCTION We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an immune checkpoint inhibitor, with or without radiotherapy in patients with advanced solid tumors. MATERIALS AND METHODS Peposertib 100-400 mg twice daily (b.i.d.) or 100-250 mg once daily (q.d.) was administered in combination with avelumab 800 mg every 2 weeks in Part A or avelumab plus radiotherapy (3 Gy/fraction × 10 days) in Part B. Part FE assessed the effect of food on the pharmacokinetics of peposertib plus avelumab. The primary endpoint in Parts A and B was dose-limiting toxicity (DLT). Secondary endpoints were safety, best overall response per RECIST version 1.1, and pharmacokinetics. The recommended phase II dose (RP2D) and maximum tolerated dose (MTD) were determined in Parts A and B. RESULTS In Part A, peposertib doses administered were 100 mg (n = 4), 200 mg (n = 11), 250 mg (n = 4), 300 mg (n = 6), and 400 mg (n = 4) b.i.d. Of DLT-evaluable patients, one each had DLT at the 250-mg and 300-mg dose levels and three had DLT at the 400-mg b.i.d. dose level. In Part B, peposertib doses administered were 100 mg (n = 3), 150 mg (n = 3), 200 mg (n = 4), and 250 mg (n = 9) q.d.; no DLT was reported in evaluable patients. Peposertib 200 mg b.i.d. plus avelumab and peposertib 250 mg q.d. plus avelumab and radiotherapy were declared as the RP2D/MTD. No objective responses were observed in Part A or B; one patient had a partial response in Part FE. Peposertib exposure was generally dose proportional. CONCLUSIONS Peposertib doses up to 200 mg b.i.d. in combination with avelumab and up to 250 mg q.d. in combination with avelumab and radiotherapy were tolerable in patients with advanced solid tumors; however, antitumor activity was limited. CLINICALTRIALS GOV IDENTIFIER NCT03724890.
Collapse
Affiliation(s)
- B Perez
- Moffitt Cancer Center, Tampa
| | | | - T U Marron
- Icahn School of Medicine at Mount Sinai, New York
| | | | - H Burris
- Sarah Cannon Research Institute, Nashville
| | - W T Iams
- Vanderbilt University Medical Center, Nashville
| | | | - J J Luke
- UPMC Hillman Cancer Center, Pittsburgh
| | - W Edenfield
- Greenville Health System, Institute for Translational Oncology Research, Greenville
| | - D Sohal
- University of Cincinnati Medical Center, Cincinnati, USA
| | - X Liao
- Merck Serono Co., Ltd. (An Affiliate of Merck KGaA), Beijing, China
| | - C Boesler
- Merck Healthcare KGaA, Darmstadt, Germany
| | - A Machl
- EMD Serono Research & Development Institute, Inc. (An Affiliate of Merck KGaA), Billerica, USA
| | - J Seebeck
- Merck Healthcare KGaA, Darmstadt, Germany
| | - A Becker
- Merck Healthcare KGaA, Darmstadt, Germany
| | - B Guenther
- Merck Healthcare KGaA, Darmstadt, Germany
| | | | | |
Collapse
|
2
|
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial. J Clin Oncol 2023; 41:5482-5492. [PMID: 38100992 DOI: 10.1200/jco.22.02777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2023] Open
Abstract
PURPOSE Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. PATIENTS AND METHODS One hundred twenty-six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (> or = 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. RESULTS Clinical benefit response was experienced by 23.8% of gemcitabine-treated patients compared with 4.8% of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18% for gemcitabine patients and 2% for 5-FU patients. Treatment was well tolerated. CONCLUSION This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.
Collapse
Affiliation(s)
- H A Burris
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - M J Moore
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - J Andersen
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - M R Green
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - M L Rothenberg
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - M R Modiano
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - M C Cripps
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - R K Portenoy
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - A M Storniolo
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - P Tarassoff
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - R Nelson
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - F A Dorr
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - C D Stephens
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| | - D D Von Hoff
- Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA
| |
Collapse
|
3
|
Peña M, Martin A, Holland P, Black LE, Peterman J, Montoya-Williams D, Burris H, Ciara N, Wooten J, Christ L, Walker W, Lilley J, Tkacs M, Scott L. Qualitative analysis of black birthing parents’ influences on infant feeding. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00554-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
4
|
Friedman C, Swanton C, Spigel D, Bose R, Burris H, Yu W, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney C, Hainsworth J, Meric-Bernstam F, Kurzrock R. 66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
5
|
Rodon J, Demanse D, Rugo H, André F, Janku F, Mayer I, Burris H, Simo R, Farooki A, Hu H, Lorenzo I, Quadt C, Juric D. 96MO A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
6
|
Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 2020; 31:861-872. [PMID: 32272210 DOI: 10.1016/j.annonc.2020.03.299] [Citation(s) in RCA: 74] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 03/15/2020] [Indexed: 01/05/2023] Open
Abstract
A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019, which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO), the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the Taiwan Oncology Society (TOS). The purpose of the meeting was to focus on what we have learnt from both microsatellite instability (MSI)/deficient mismatch repair (dMMR) biomarkers in predicting the efficacy of anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) immunotherapy, and the neurotrophic tyrosine receptor kinase (NTRK) gene fusions in predicting the efficacy of inhibitors of the tropomyosin receptor kinase (TRK) proteins across a range of solid tumour types. The recent regulatory approvals of the anti-PD-1 antibody pembrolizumab and the TRK inhibitors larotrectinib and entrectinib, based on specific tumour biomarkers rather than specific tumour type, have heralded a paradigm shift in cancer treatment approaches. The purpose of the meeting was to develop international expert consensus recommendations on the use of such tumour-agnostic treatments in patients with solid tumours. The aim was to generate a reference document for clinical practice, for pharmaceutical companies in the design of clinical trials, for ethics committees in the approval of clinical trial protocols and for regulatory authorities in relation to drug approvals, with a particular emphasis on diagnostic testing and patient selection.
Collapse
Affiliation(s)
- T Yoshino
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
| | - G Pentheroudakis
- Department of Medical Oncology, University of Ioannina, Ioannina, Greece
| | - S Mishima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - M J Overman
- Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - K-H Yeh
- Department of Medical Oncology, National Taiwan University Cancer Center and Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
| | - E Baba
- Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Naito
- Department of Experimental Therapeutics/Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - F Calvo
- Department of Clinical Pharmacology, University of Paris and Institute Gustave Roussy, Villejuif, France
| | - A Saxena
- Department of Medicine, Division of Hematology & Medical Oncology, Thoracic Oncology Service, Weill Cornell Medicine, New York, USA
| | - L-T Chen
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - M Takeda
- Department of Medical Oncology, Kindai University, Osaka, Japan
| | - A Cervantes
- CIBERONC, Department of Medical Oncology, Institute of Health Research, INCLIVIA, University of Valencia, Valencia, Spain
| | - H Taniguchi
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - K Yoshida
- Department of Surgical Oncology, Gifu University, Graduate School of Medicine, Gifu, Japan
| | - Y Kodera
- Department of Gastrointestinal Surgery, Nagoya University, Nagoya, Japan
| | - Y Kitagawa
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - J Tabernero
- Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain
| | - H Burris
- The Sarah Cannon Research Institute, Nashville, USA
| | | |
Collapse
|
7
|
Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 2020; 31:412-421. [PMID: 32067683 PMCID: PMC9743163 DOI: 10.1016/j.annonc.2019.11.018] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Revised: 11/08/2019] [Accepted: 11/28/2019] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. PATIENTS AND METHODS MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR). RESULTS As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred. CONCLUSIONS Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
Collapse
Affiliation(s)
- R. Kurzrock
- Moores Cancer Center, UC San Diego, San Diego,Correspondence to: Dr Razelle Kurzrock, Moores Cancer Center, UC San Diego, 3855 Health Sciences Dr. #1503, La Jolla, CA 92093, USA. Tel: +1-858-246-1102; Fax: +1-858-246-1915, (R. Kurzrock)
| | - D. W. Bowles
- Department of Medicine, University of Colorado Denver, Aurora
| | - H. Kang
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore
| | - F. Meric-Bernstam
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston
| | - J. Hainsworth
- Oncology Department, Sarah Cannon Research Institute, Nashville,Tennessee Oncology, PLLC, Nashville
| | - D. R. Spigel
- Oncology Department, Sarah Cannon Research Institute, Nashville,Tennessee Oncology, PLLC, Nashville
| | - R. Bose
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis
| | - H. Burris
- Oncology Department, Sarah Cannon Research Institute, Nashville,Tennessee Oncology, PLLC, Nashville
| | - C. J. Sweeney
- Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - M. S. Beattie
- Department of Product Development, Medical Affairs, F. Hoffmann-La Roche, South San Francisco, USA
| | - S. Blotner
- Department of Biostatistics, South San Francisco, USA
| | - K. Schulze
- Department of Oncology Biomarker Development, South San Francisco, USA
| | - V. Cuchelkar
- Department of BioOncology, Genentech, Inc., South San Francisco, USA
| | - C. Swanton
- Department of Tumour Biology, Francis Crick Institute, London, UK
| |
Collapse
|
8
|
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2019; 30:1842. [PMID: 31407010 PMCID: PMC6927326 DOI: 10.1093/annonc/mdz215] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Burris HA, Chan A, Im SA, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC). Here we further evaluate the safety of RIB-based regimens of interest for the proposed indication (i.e. with a non-steroidal aromatase inhibitor [NSAI] or fulvestrant [FUL]) using pooled data from three Phase III trials (MONALEESA [ML]-2 [NCT01958021], -3 [NCT02422615], and -7 [NCT02278120]).
Methods: Postmenopausal pts with HR+, HER2– ABC received RIB (600 mg/day; 3-weeks-on/1-week-off) or PBO + letrozole (LET; 2.5 mg/day; ML-2 [no prior ET for ABC]) or FUL (500 mg, Days 1 and 15 of Cycle 1, then Day 1 of every cycle thereafter; ML-3; no or ≤1 prior line of ET for ABC]). Premenopausal pts (ML-7; no prior ET and ≤1 chemotherapy for ABC]) received RIB or PBO + anastrozole (1 mg/day)/LET (2.5 mg/day) + goserelin (3.6 mg every 28 days). Adverse events (AEs) were characterized per Common Terminology Criteria for Adverse Events v4.03; safety analyses included time to first event, duration of event, and rate of associated RIB/PBO discontinuations.
Results: Data for 1883 pts were pooled; 1065 pts received RIB + ET and 818 pts received PBO + ET (median exposure to study treatment: 17 and 13 months, respectively). Exposure-adjusted incidence rates for AEs of special interest were 561 and 131 per 100 pt-years in the RIB and PBO arms, respectively. The most common all-causality Grade 3/4 AEs (≥10% in any arm; RIB vs PBO) were neutropenia (59% vs 2%), leukopenia (18% vs 1%), and hypertension (13% vs 13%). A new Fridericia's corrected QT interval (QTcF) >480 ms occurred in (n/N) 52/1054 (5%) vs 11/814 (1%) pts in the RIB vs PBO arms; a new QTcF >500 ms occurred in 14/1054 (1%) vs 1/814 (<1%) pts. Median time to first event for Grade ≥2 neutropenia, elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), and QTc prolongation in the RIB arm was 2, 12, and 2 weeks, respectively; median duration of first Grade ≥2 event was 4, 4, and 2 weeks. In the RIB arm vs PBO arms, 7% vs 3% of pts discontinued study treatment due to AEs; common all-grade AEs leading to RIB/PBO discontinuation (≥2% in any arm) were elevated ALT (4% vs <1%) and elevated AST (2% vs 1%). Discontinuation due to QT prolongation occurred in 4 pts in the RIB arm and 2 in the PBO arm (both <1%). All-grade serious AEs occurred in 25% of pts in the RIB arm vs 15% of pts in the PBO arm.
Conclusions: RIB in combination with various ET partners continues to demonstrate a predictable and manageable tolerability profile across a broad population of pts with HR+, HER2– ABC.
Citation Format: Burris HA, Chan A, Im S-A, Chia S, Tripathy D, Esteva FJ, Campone M, Bardia A, Kong O, Bao W, Diaz-Padilla I, Rodriguez Lorenc K, Yardley DA. Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-15.
Collapse
Affiliation(s)
- HA Burris
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Chan
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S-A Im
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - S Chia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - D Tripathy
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - FJ Esteva
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - M Campone
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - A Bardia
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - O Kong
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - W Bao
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - I Diaz-Padilla
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - K Rodriguez Lorenc
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| | - DA Yardley
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville; Breast Cancer Research Centre – WA, Nedlands, Australia; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, Korea; BC Cancer Agency, Vancouver, Canada; The University of Texas MD Anderson Cancer Center, Houston; NYU Langone Health, New York; Centre René Gauducheau, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Novartis Pharmaceuticals Corporation, East Hanover; Novartis Pharma AG, Basel, Switzerland; Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
| |
Collapse
|
10
|
Yardley DA, Chan A, Nusch A, Sonke GS, Yap YS, Bachelot T, Esteva FJ, Slamon DJ, Burris HA, Gaur A, Kong O, Diaz-Padilla I, Rodriguez Lorenc K, Wheatley-Price P. Abstract P6-18-07: Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-07] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients (pts) with advanced breast cancer (ABC) who present with visceral metastases (mets) have a poorer prognosis vs pts with non-visceral disease. In the Phase III MONALEESA (ML) trials, ribociclib (RIB) + endocrine therapy (ET) prolonged progression-free survival (PFS) vs placebo (PBO) + ET in hormone receptor-positive (HR+), HER2-negative (HER2–) ABC. Here we show data for pts with and without visceral mets from the ML-2, -3, and -7 trials.
Methods: Data were collated from 3 trials in HR+, HER2– ABC: in ML-2 (NCT01958021; data cutoff [DCO] Jan 2/4, 2017), postmenopausal pts (no prior ET for ABC) received RIB or PBO + letrozole; in ML-3 (NCT02422615; DCO Nov 3, 2017), postmenopausal pts (no prior ET for ABC subgroup only) received RIB or PBO + fulvestrant; in ML-7 (NCT02278120; DCO Aug 20, 2017), premenopausal pts (no prior ET and ≤1 chemotherapy for ABC) received RIB or PBO + goserelin + anastrozole/letrozole. Endpoints; primary: local PFS; secondary: overall response rate (ORR), clinical benefit rate (CBR), safety.
Results: Of all 820 pts treated with RIB + ET, 484 (59%) had visceral mets (ML-2 197/334; ML-3 137/238; ML-7 150/248); of all 710 pts treated with PBO + ET, 416 (59%) had visceral mets (ML-2 196/334; ML-3 77/129; ML-7 143/247). Median PFS was prolonged for RIB vs PBO in pts with and without visceral mets (Table). ORR and CBR were also higher for RIB vs PBO in pts with and without visceral mets. The most common (≥10% of pts in any arm) Grade [G] 3 and 4 adverse events (AEs) for each trial are shown in the table; no G4 AEs occurred in ≥10% of pts in ML-3.
Visceral metsNo visceral metsML-2 Median PFS (RIB/PBO), months (95% CI)24.9 (22.2–30.9)/13.4 (12.7–16.5)25.3 (22.2–NR)/18.2 (15.0–24.6)Hazard ratio (95% CI)0.538 (0.408–0.709)0.634 (0.448–0.897) ORR (RIB/PBO),* %48/3735/17 CBR (RIB/PBO),† %79/7282/75 Most common (≥10% in any arm) G3 AEs (RIB/PBO), %Neutropenia56/147/1Leukopenia19/121/<1Hypertension11/1115/15 Most common (≥10% in any arm) G4 AEs (RIB/PBO), %Neutropenia10/09/0 ML-3 Median PFS (RIB/PBO), months (95% CI)NR (19.1–NR)/16.5 (9.0–NR)NR (NR–NR)/21.9 (14.8–NR)Hazard ratio (95% CI)0.610 (0.403–0.926)0.521 (0.295–0.921) ORR (RIB/PBO),* %46/2931/21 CBR (RIB/PBO),† %74/6075/81 Most common (≥10% in any arm) G3 AEs (RIB/PBO), %Neutropenia50/045/0Leukopenia12/010/0Increased ALT6/012/0 ML-7 Median PFS (RIB/PBO), months (95% CI)23.8 (14.8–NR)/10.4 (7.2–12.9)27.5 (NR–NR)/19.3 (16.5–NR)Hazard ratio (95% CI)0.507 (0.367–0.700)0.609 (0.377–0.984) ORR (RIB/PBO),* %45/3630/19 CBR (RIB/PBO),† %79/5783/81 Most common (≥10% in any arm) G3 AEs (RIB/PBO), %Neutropenia54/356/4Leukopenia14/116/1 Most common (≥10% in any arm) G4 AEs (RIB/PBO), %Neutropenia11/<19/0CI, confidence interval; NR, not reached. *ORR = complete response + partial response; †CBR = complete response + partial response + (stable disease + non-complete response/non-progressive disease ≥24 weeks).
Conclusions: Although the presence of visceral mets is associated with a poorer prognosis, RIB + ET is an effective and well-tolerated treatment option for pts with HR+, HER2– ABC irrespective of the presence of visceral mets.
Citation Format: Yardley DA, Chan A, Nusch A, Sonke GS, Yap Y-S, Bachelot T, Esteva FJ, Slamon DJ, Burris HA, Gaur A, Kong O, Diaz-Padilla I, Rodriguez Lorenc K, Wheatley-Price P. Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-07.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - A Chan
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - A Nusch
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - GS Sonke
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - Y-S Yap
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - T Bachelot
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - FJ Esteva
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - DJ Slamon
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - HA Burris
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - A Gaur
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - O Kong
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - I Diaz-Padilla
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - K Rodriguez Lorenc
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| | - P Wheatley-Price
- Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, TN; Breast Cancer Research Centre, Nedlands, Western Australia, Australia; Practice for Haematology and Internal Oncology, Velbert, Germany; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; National Cancer Centre Singapore, Singapore, Singapore; Centre Léon Bérard, Lyon, France; NYU Langone Health, New York, NY; UCLA Medical Center, Santa Monica, CA; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Novartis Healthcare Pvt. Ltd., Hyderabad, India; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; University of Ottawa, Ottawa, ON, Canada
| |
Collapse
|
11
|
Im SA, Bang YJ, Oh DY, Giaccone G, Bauer T, Nordstrom J, Li H, Moore P, Hong S, Baughman J, Rock E, Burris H. Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Margetuximab is an Fc-optimized anti-HER2 antibody that recognizes the same epitope as trastuzumab. Margetuximab has increased affinity for the activating CD16A Fc-receptor on NK cells and macrophages as well as decreased affinity for the inhibitory CD32B receptor compared to trastuzumab. In a Phase 1 study (NCT01148849) of 66 patients with relapsed or metastatic HER2+ cancer across multiple indications, margetuximab was well tolerated at all doses. Among 60 response-evaluable patients, confirmed partial response (PR) and stable disease (SD) were seen in 7 (12%) and 30 (50%) patients, respectively. Tumor reductions occurred in 18/23 (78%) evaluable breast cancer patients. Ex-vivo analyses of patient peripheral blood mononuclear cell samples confirmed margetuximab's ability to enhance antibody dependent cell-mediated cytotoxicity over that from trastuzumab. We report on 3 breast cancer patients with prior anti-HER2 therapy failure with durable (≥ 3.5 years) SD (1) or PR (2).
Methods
Enrolled patients had histologically/cytologically-confirmed carcinoma with documented HER2 overexpression by immunohistochemistry (2+ or 3+) and disease progression during/following last therapy. Eligibility included life expectancy ≥3 months; performance status ≤1; measurable disease by Response Criteria for Solid Tumors 1.1; adequate bone marrow, renal, hepatic function; and left ventricular ejection fraction ≥50%. Margetuximab was given by intravenous infusion at 0.1 – 6.0 mg/kg for 3 of every 4 weeks or once every 3 weeks (10 – 18 mg/kg).
Results
Three of 17 HER2 3+ metastatic breast cancer patients received long-term margetuximab. Patient 35 had 3 prior regimens (adjuvant doxorubicin+cyclophosphamide followed by docetaxol+trastuzumab; gemcitabine+vinorelbine; lapatinib+capecitabine) and received margetuximab at 10 mg/kg q3wk, 88 cycles to date, with PR achieved Cycle 1 Day 43, maintained 4.4 years. Patient 44 had 3 prior regimens for metastatic disease (docetaxel+trastuzumab+pertuzumab; doxorubicin+cyclophosphamide; lapatinib+capecitabine) and received margetuximab at 15 mg/kg q3wk, 79 cycles to date with SD for 4.3 years. Patient 50 had 4 prior regimens for recurrent/metastatic disease (tamoxifen; anastrozole; capecitabine+trastuzumab; lapatinib+capecitabine) and received margetuximab dose of 18 mg/kg q3wk with PR achieved Cycle 1 Day 43, maintained 3.5 years. Progression was noted at Cycle 57, and margetuximab continues at 63 cycles to date. No cardiac toxicities were found during long-term follow-up for these 3 patients and there were no treatment-related adverse events ≥Grade 3.
Conclusions
Margetuximab is well-tolerated without cardiac toxicities in long-term responders, with single-agent activity including durable responses in heavily pre-treated metastatic breast cancer. A Phase 3, randomized, multi-center clinical trial (SOPHIA; NCT02492711) is enrolling patients with metastatic breast cancer, comparing margetuximab plus chemotherapy to trastuzumab plus chemotherapy in patients who have received 1 to 3 lines of therapy for advanced disease.
Citation Format: Im S-A, Bang Y-J, Oh D-Y, Giaccone G, Bauer T, Nordstrom J, Li H, Moore P, Hong S, Baughman J, Rock E, Burris H. Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-11.
Collapse
Affiliation(s)
- S-A Im
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - Y-J Bang
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - D-Y Oh
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - G Giaccone
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - T Bauer
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - J Nordstrom
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - H Li
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - P Moore
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - S Hong
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - J Baughman
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - E Rock
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| | - H Burris
- Seoul National University Hospital, Seoul, Republic of Korea; Georgetown University, Washington, DC; Sarah Cannon Research Institute, Nashville, TN; MacroGenics, Inc., Rockville, MD
| |
Collapse
|
12
|
Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019; 30:325-331. [PMID: 30624546 PMCID: PMC6386027 DOI: 10.1093/annonc/mdy539] [Citation(s) in RCA: 93] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours harbouring NTRK gene fusions. PATIENTS AND METHODS This multi-centre, phase I dose escalation study enrolled adults with metastatic solid tumours, regardless of NTRK gene fusion status. Key inclusion criteria included evaluable and/or measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Larotrectinib was administered orally once or twice daily, on a continuous 28-day schedule, in increasing dose levels according to a standard 3 + 3 dose escalation scheme. The primary end point was the safety of larotrectinib, including dose-limiting toxicity. RESULTS Seventy patients (8 with tumours with NTRK gene fusions; 62 with tumours without a documented NTRK gene fusion) were enrolled to 6 dose cohorts. There were four dose-limiting toxicities; none led to study drug discontinuation. The maximum tolerated dose was not reached. Larotrectinib-related adverse events were predominantly grade 1; none were grade 4 or 5. The most common grade 3 larotrectinib-related adverse event was anaemia [4 (6%) of 70 patients]. A dose of 100 mg twice daily was recommended for phase II studies based on tolerability and antitumour activity. In patients with evaluable TRK fusion cancer, the objective response rate by independent review was 100% (eight of the eight patients). Eight (12%) of the 67 assessable patients overall had an objective response by investigator assessment. Median duration of response was not reached. Larotrectinib had limited activity in tumours with NTRK mutations or amplifications. Pharmacokinetic analysis showed exposure was generally proportional to administered dose. CONCLUSIONS Larotrectinib was well tolerated, demonstrated activity in all patients with tumours harbouring NTRK gene fusions, and represents a new treatment option for such patients. CLINCALTRIALS.GOV NUMBER NCT02122913.
Collapse
Affiliation(s)
- D S Hong
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
| | - T M Bauer
- Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, USA
| | - J J Lee
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA
| | - A Dowlati
- Department of Medicine-Hematology and Oncology, UH Cleveland Medical Center, Cleveland, USA
| | - M S Brose
- Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, USA
| | - A F Farago
- Department of Medicine, Massachusetts General Hospital, Boston, USA
| | - M Taylor
- The Knight Cancer Institute, Oregon Health & Science University, Portland, USA
| | - A T Shaw
- Department of Medicine, Massachusetts General Hospital, Boston, USA
| | - S Montez
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - F Meric-Bernstam
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S Smith
- Loxo Oncology, South San Francisco, USA
| | - B B Tuch
- Loxo Oncology, South San Francisco, USA
| | - K Ebata
- Loxo Oncology, South San Francisco, USA
| | | | - M C Cox
- Loxo Oncology, South San Francisco, USA
| | - H A Burris
- Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, USA
| | - R C Doebele
- Department of Medicine, University of Colorado Cancer Center, Aurora, USA
| |
Collapse
|
13
|
Johnson M, Patel M, Ulahannan S, Hansen A, George B, Chu QC, Elgadi M, Ge M, Duffy C, Graeser R, Khedkar S, Jones S, Burris H. Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Sobrero A, Lenz HJ, Eng C, Scheithauer W, Middleton G, Chen W, Esser R, Nippgen J, Burris H. Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Blackwell KL, Paluch-Shimon S, Campone M, Conte P, Petrakova K, Favret A, Blau S, Beck JT, Miller M, Sutradhar S, Monaco M, Burris HA. Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the Phase III MONALEESA-2 study (NCT01958021), ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor [CDK4/6i]) + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). The optimal treatment sequence following first-line CDK4/6i-based therapy is not yet known. Here we report the subsequent therapies received following discontinuation from MONALEESA-2.
Methods: The MONALEESA-2 study enrolled 668 patients (pts) with HR+, HER2– ABC. Pts were randomized 1:1 to receive RIB (600 mg/day; 3-weeks-on/1-week-off) + LET (2.5 mg/day; continuous) or PBO + LET. Following discontinuation of MONALEESA-2 study treatment, pts were followed for information regarding post-study treatment, including type and duration of therapy.
Results: At data cut-off (January 2, 2017), the median duration of follow-up was 26.4 months. Median PFS was 25.3 vs 16.0 months in the RIB + LET vs PBO + LET arms (hazard ratio=0.568; 95% confidence interval [CI]: 0.457–0.704; p=9.63x10–8). 203 (60.8%) vs 246 (73.7%) pts had discontinued RIB + LET vs PBO + LET. The median time to end of treatment was 20.3 months in the RIB + LET arm vs 13.7 months in the PBO + LET arm. First subsequent antineoplastic treatment was reported for 172/203 (84.7%) vs 212/246 (86.2%) pts who received RIB + LET vs PBO + LET; second subsequent therapy was reported for 45/203 (22.2%) vs 68/246 (27.6%) pts. The median time to first subsequent therapy (from randomization to the first post-study dose of therapy) was 24.2 (95% CI: 20.9–27.6) vs 16.7 (95% CI: 14.8–19.3) months in pts who received RIB + LET vs PBO + LET; median time to initiation of second subsequent therapy was not reached in either arm. The most common type of first subsequent therapy was single-agent hormonal therapy in 90 (44.3%) vs 87 (35.4%) pts who discontinued RIB + LET vs PBO + LET; chemotherapy was the most common second subsequent therapy in 20 (9.9%) vs 36 (14.6%) pts. Chemotherapy alone was the first subsequent treatment after MONALEESA-2 discontinuation in 32 (15.8%) vs 55 (22.4%) pts treated with RIB + LET vs PBO + LET.
Conclusions: RIB + LET significantly prolongs PFS and delays the start of subsequent lines of therapy vs PBO + LET in pts with HR+, HER2– ABC. The most common first subsequent therapy following discontinuation of RIB + LET or PBO + LET was single-agent hormonal therapy, and fewer pts treated with RIB + LET received subsequent chemotherapy compared with those who received PBO + LET.
Citation Format: Blackwell KL, Paluch-Shimon S, Campone M, Conte P, Petrakova K, Favret A, Blau S, Beck JT, Miller M, Sutradhar S, Monaco M, Burris HA. Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-18.
Collapse
Affiliation(s)
- KL Blackwell
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - S Paluch-Shimon
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - M Campone
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - P Conte
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - K Petrakova
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - A Favret
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - S Blau
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - JT Beck
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - M Miller
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - S Sutradhar
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - M Monaco
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| | - HA Burris
- Duke University Medical Center, Durham, NC; Sheba Medical Center, Ramat Gan, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; University of Padova and Istituto Oncologico Veneto, IRCCS, Padova, Italy; Masaryk Memorial Cancer Institute, Brno, Czech Republic; Virginia Cancer Specialists, Arlington, VA; Rainier Hematology–Oncology, Northwest Medical Specialties, Puyallup, WA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
16
|
Modi S, Pusztai L, Forero A, Mita M, Miller KD, Weise A, Krop I, Burris H, Kalinsky K, Tsai M, Liu MC, Hurvitz SA, Wilks S, Ademuyiwa F, Diab S, Han HS, Kato G, Nanda R, O'Shaughnessy J, Kostic A, Li M, Specht J. Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd3-14] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
LIV-1, a transmembrane protein and downstream target of STAT3, is highly expressed in breast cancer cells. It is associated with lymph node involvement and metastatic progression. SGN-LIV1A is an anti-LIV-1 antibody conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE). Upon binding to cell-surface LIV-1, SGN-LIV1A is internalized and releases MMAE, which disrupts microtubulin and induces apoptosis.
Methods
This ongoing, phase 1 study evaluates safety, tolerability, pharmacokinetics, and antitumor activity of SGN-LIV1A (q3wks IV) in women with LIV-1-positive, unresectable, locally advanced or metastatic breast cancer (LA/MBC) (NCT01969643). Patients (pts) with measurable disease and ≥2 prior cytotoxic regimens for LA/MBC are eligible. Pts with ≥ Grade 2 neuropathy are excluded. Response is assessed per RECIST v1.1; pts with stable disease (SD) or better can continue treatment until disease progression or intolerable toxicity. At completion of dose escalation in hormone receptor-positive/HER2-negative (HR+/HER2–) and triple-negative (TN) pts, expansion cohorts were opened to further evaluate safety and antitumor activity of monotherapy in TN pts. Tumor biopsies are evaluated for LIV-1 expression.
Results
To date, 69 pts (18 HR+/HER2–, 51 TN) have received a median of 3 cycles (range, 1–12) of SGN-LIV1A at doses of 0.5–2.8 mg/kg. Median age was 56 yrs. Pts had a median of 3 prior cytotoxic regimens for LA/MBC; 58 had visceral disease and 37 had bone metastases. No dose-limiting toxicities (DLTs) occurred in 19 DLT-evaluable pts; maximum tolerated dose was not exceeded at 2.8 mg/kg. Expansion cohorts of TN pts were opened at 2.0 and 2.5 mg/kg. Treatment-emergent adverse events (AEs) reported in ≥25% of pts were fatigue (59%), nausea (51%), peripheral neuropathy (44%), alopecia (36%), decreased appetite (33%), constipation (30%), abdominal pain, diarrhea, and neutropenia (25% each). Most AEs were Grade 1/2; AEs ≥ Grade 3 included neutropenia (25%) and anemia (15%). Febrile neutropenia occurred in 2 pts whose total dose exceeded 200 mg per cycle, including 1 treatment-related death due to sepsis. No other treatment-related deaths occurred on-study. Seven pts discontinued treatment due to AEs. In dose escalation, activity was observed in 17 efficacy evaluable (EE) HR+/HER2- pts, with a disease control rate (DCR= CR+PR+SD) of 59% (10 SD), including 1 pt with SD ≥24 wks. Among the 44 EE TN pts (dose escalation plus expansion cohorts), the objective response rate (ORR) was 32% (14 PR) with a confirmed PR rate of 21%, DCR was 64% (14 PR, 14 SD), and clinical benefit rate (CBR=CR+PR+SD ≥24 wks) was 36% (16 pts). For TN pts, median PFS was 11.3 wks (95% CI: 6.1, 17.1); 10 pts remain on treatment.
Of 631 MBC tumor samples of all clinical subtypes evaluated for LIV-1, 91% were positive; 75% had moderate-to-high expression (H-score ≥100).
Conclusions
LIV-1 is expressed in almost all MBC tumors. SGN-LIV1A monotherapy was generally well tolerated and showed encouraging antitumor activity in heavily pretreated TN MBC, with a PR rate of 32%, confirmed PR rate of 21%, and CBR (≥24 wks) of 36%. Response duration data continue to evolve. Enrollment continues in the TN monotherapy expansion cohort.
Citation Format: Modi S, Pusztai L, Forero A, Mita M, Miller KD, Weise A, Krop I, Burris III H, Kalinsky K, Tsai M, Liu MC, Hurvitz SA, Wilks S, Ademuyiwa F, Diab S, Han HS, Kato G, Nanda R, O'Shaughnessy J, Kostic A, Li M, Specht J. Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD3-14.
Collapse
Affiliation(s)
- S Modi
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - L Pusztai
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - A Forero
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - M Mita
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - KD Miller
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - A Weise
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - I Krop
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - H Burris
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - K Kalinsky
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - M Tsai
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - MC Liu
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - SA Hurvitz
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - S Wilks
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - F Ademuyiwa
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - S Diab
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - HS Han
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - G Kato
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - R Nanda
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - J O'Shaughnessy
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - A Kostic
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - M Li
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| | - J Specht
- Memorial Sloan Kettering Cancer Center, New York, NY; Yale Cancer Center, Yale School of Medicine, New Haven, CT; University of Alabama at Birmingham, Birmingham, AL; Cedars-Sinai Medical Center, Los Angeles, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Dana-Farber Cancer Institute, Boston, MA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Columbia University Medical Center, New York, New York, NY; Virginia Piper Cancer Institute, Allina Health, Minneapolis, MN; Mayo Clinic, Rochester, MN; University of California, Los Angeles, Los Angeles, CA; Texas Oncology, San Antonio, TX; Washington University in St. Louis, St. Louis, MO; US Oncology Denver, Denver, CO; Moffitt Cancer Center, Tampa, FL; Virginia G. Piper Cancer Care Network, Scottsdale, AZ; University of Chicago, Chicago, IL; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Seattle Genetics, Inc., Bothell, WA; Seattle Cancer Care Allia
| |
Collapse
|
17
|
Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 2017; 27:2124-2130. [PMID: 27793850 DOI: 10.1093/annonc/mdw401] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Accepted: 08/16/2016] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND MUC16 is a tumor-specific antigen overexpressed in ovarian (OC) and pancreatic (PC) cancers. The antibody-drug conjugate (ADC), DMUC5754A, contains the humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE). PATIENTS AND METHODS This phase I study evaluated safety, pharmacokinetics (PK), and pharmacodynamics of DMUC5754A given every 3 weeks (Q3W, 0.3-3.2 mg/kg) or weekly (Q1W, 0.8-1.6 mg/kg) to patients with advanced recurrent platinum-resistant OC or unresectable PC. Biomarker studies were also undertaken. RESULTS Patients (66 OC, 11 PC) were treated with DMUC5754A (54 Q3W, 23 Q1W). Common related adverse events (AEs) in >20% of patients (all grades) over all dose levels were fatigue, peripheral neuropathy, nausea, decreased appetite, vomiting, diarrhea, alopecia, and pyrexia in Q3W patents, and nausea, vomiting, anemia, fatigue, neutropenia, alopecia, decreased appetite, diarrhea, and hypomagnesemia in Q1W patients. Grade ≥3-related AE in ≥5% of patients included neutropenia (9%) and fatigue (7%) in Q3W patients, and neutropenia (17%), diarrhea (9%), and hyponatremia (9%) in Q1W patients. Plasma antibody-conjugated MMAE (acMMAE) and serum total antibody exhibited non-linear PK across tested doses. Minimal accumulation of acMMAE, total antibody, or unconjugated MMAE was observed. Confirmed responses (1 CR, 6 PRs) occurred in OC patients whose tumors were MUC16-positive by IHC (2+ or 3+). Two OC patients had unconfirmed PRs; six OC patients had stable disease lasting >6 months. For CA125, a cut-off of ≥70% reduction was more suitable for monitoring treatment response due to the binding and clearance of serum CA125 by MUC16 ADC. We identified circulating HE4 as a potential novel surrogate biomarker for monitoring treatment response of MUC16 ADC and other anti-MUC16 therapies in OC. CONCLUSIONS DMUC5754A has an acceptable safety profile and evidence of anti-tumor activity in patients with MUC16-expressing tumors. Objective responses were only observed in MUC16-high patients, although prospective validation is required. CLINICAL TRIAL NUMBER NCT01335958.
Collapse
Affiliation(s)
- J F Liu
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - K N Moore
- Division of Gynecologic Oncology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City
| | - M J Birrer
- Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston
| | - S Berlin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.,Department of Oncology, New England Cancer Care Specialists, Kennebunk
| | - U A Matulonis
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - B Wolpin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
| | - K A Poon
- Early Development, Genentech, South San Francisco, USA
| | - R Firestein
- Early Development, Genentech, South San Francisco, USA
| | - J Xu
- Early Development, Genentech, South San Francisco, USA
| | - R Kahn
- Early Development, Genentech, South San Francisco, USA
| | - Y Wang
- Early Development, Genentech, South San Francisco, USA
| | - K Wood
- Early Development, Genentech, South San Francisco, USA
| | - W C Darbonne
- Early Development, Genentech, South San Francisco, USA
| | - M R Lackner
- Early Development, Genentech, South San Francisco, USA
| | - S K Kelley
- Early Development, Genentech, South San Francisco, USA
| | - X Lu
- Early Development, Genentech, South San Francisco, USA
| | - Y J Choi
- Early Development, Genentech, South San Francisco, USA
| | - D Maslyar
- Early Development, Genentech, South San Francisco, USA
| | - E W Humke
- Early Development, Genentech, South San Francisco, USA
| | - H A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
18
|
Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol 2017; 28:528-534. [PMID: 28426123 PMCID: PMC5391701 DOI: 10.1093/annonc/mdw651] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts. Patients and methods Eligible patients had Child-Pugh A liver function and ≤1 prior systemic anticancer regimen, completed ≥4 weeks before study entry. The cabozantinib starting dose was 100 mg daily. After an initial 12-week cabozantinib treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week 12, and the primary endpoint of the randomized stage was progression-free survival (PFS). Results Among the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response (PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with ≥1 post-baseline scan, 78% had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (>50% reduction from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and ≥1 post-baseline measurement. Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day 1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution, were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients. Conclusions Cabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP. Adverse events were managed with dose reductions. Trial registration number NCT00940225.
Collapse
Affiliation(s)
- R K Kelley
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, USA
| | - C Verslype
- Gastroenterology & Hepatology, University Hospitals and KU Leuven, Leuven, Belgium
| | - A L Cohn
- Rocky Mountain Cancer Center, LLP, Denver, USA
| | - T-S Yang
- Department of Internal Medicine, Chang Gung Memorial Hospital, Tao-Yuan
| | - W-C Su
- Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - H Burris
- Sarah Cannon Research Institute, Nashville, USA,Tennessee Oncology, Nashville, USA
| | - F Braiteh
- US Oncology Research/Comprehensive Cancer Centers NV, Las Vegas, USA
| | - N Vogelzang
- US Oncology Research/Comprehensive Cancer Centers NV, Las Vegas, USA
| | - A Spira
- US Oncology Research and Virginia Cancer Specialists, Fairfax, USA
| | - P Foster
- Exelixis, Inc, South San Francisco, USA
| | - Y Lee
- Exelixis, Inc, South San Francisco, USA
| | - E Van Cutsem
- Gastroenterology & Hepatology, University Hospitals and KU Leuven, Leuven, Belgium
| |
Collapse
|
19
|
Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol 2017; 28:2866-2873. [PMID: 28945887 PMCID: PMC5834148 DOI: 10.1093/annonc/mdx490] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Genomic changes that occur in breast cancer during the course of disease have been informed by sequencing of primary and metastatic tumor tissue. For patients with relapsed and metastatic disease, evolution of the breast cancer genome highlights the importance of using a recent sample for genomic profiling to guide clinical decision-making. Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative. PATIENTS AND METHODS Hybrid capture-based genomic profiling was carried out on ctDNA from 254 female patients with estrogen receptor-positive breast cancer. Peripheral blood samples were submitted by clinicians in the course of routine clinical care between May 2016 and March 2017. Sequencing of 62 genes was carried out to a median unique coverage depth of 7503×. Genomic alterations (GAs) in ctDNA were evaluated and compared with matched tissue samples and genomic datasets of tissue from breast cancer. RESULTS At least 1 GA was reported in 78% of samples. Frequently altered genes were TP53 (38%), ESR1 (31%) and PIK3CA (31%). Temporally matched ctDNA and tissue samples were available for 14 patients; 89% of mutations detected in tissue were also detected in ctDNA. Diverse ESR1 GAs including mutation, rearrangement and amplification, were observed. Multiple concurrent ESR1 GAs were observed in 40% of ESR1-altered cases, suggesting polyclonal origin; ESR1 compound mutations were also observed in two cases. ESR1-altered cases harbored co-occurring GAs in PIK3CA (35%), FGFR1 (16%), ERBB2 (8%), BRCA1/2 (5%), and AKT1 (4%). CONCLUSIONS GAs relevant to relapsed/metastatic breast cancer management were identified, including diverse ESR1 GAs. Genomic profiling of ctDNA demonstrated sensitive detection of mutations found in tissue. Detection of amplifications was associated with ctDNA fraction. Genomic profiling of ctDNA may provide a complementary and possibly alternative approach to tissue-based genomic testing for patients with estrogen receptor-positive metastatic breast cancer.
Collapse
Affiliation(s)
- J H Chung
- Foundation Medicine, Inc., Cambridge.
| | - D Pavlick
- Foundation Medicine, Inc., Cambridge
| | | | | | - L Young
- Foundation Medicine, Inc., Cambridge
| | - B Forcier
- Foundation Medicine, Inc., Cambridge
| | - P Ye
- Avera Cancer Institute, Sioux Falls
| | - M K Levin
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas
| | | | - H Burris
- Sarah Cannon Research Institute, Nashville
| | - L M Gay
- Foundation Medicine, Inc., Cambridge
| | | | | | | | | | - D M Nguyen
- Sutter Medical Group of the Redwoods, Santa Rosa
| | - S Ganesan
- Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick
| | - B H Park
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore
| | - L T Vahdat
- Weill Cornell Breast Center, Weill Cornell Medicine, New York
| | | | - T I Mughal
- Foundation Medicine, Inc., Cambridge; Tufts University Medical Center, Boston
| | - L Pusztai
- Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas
| | | | - J S Ross
- Foundation Medicine, Inc., Cambridge; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, USA. mailto:
| | - S M Ali
- Foundation Medicine, Inc., Cambridge
| |
Collapse
|
20
|
Moore K, Cadoo K, Chambers S, Ghamande S, Konecny G, Oza A, Chen LM, Konstantinopoulos P, Lea J, Spitz D, Uyar D, Mugundu G, Laing N, Strickland D, Jones S, Burris H, Spigel D, Hamilton E. A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Garcia-Corbacho J, Spira A, Boni V, Feliu J, Middleton M, Burris H, Yang Weaver A, Will M, Harding J, Meric-Bernstam F, Heinemann V. PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.055] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol 2017; 28:855-861. [PMID: 28119295 DOI: 10.1093/annonc/mdx002] [Citation(s) in RCA: 158] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Indexed: 12/26/2022] Open
Abstract
Background Margetuximab is an anti-HER2 antibody that binds with elevated affinity to both the lower and higher affinity forms of CD16A, an Fc-receptor important for antibody dependent cell-mediated cytotoxicity (ADCC) against tumor cells. A Phase 1 study was initiated to evaluate the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of margetuximab in patients with HER2-overexpressing carcinomas. Patients and methods Patients with HER2-positive breast or gastric cancer, or other carcinomas that overexpress HER2, for whom no standard therapy was available, were treated with margetuximab by intravenous infusion at doses of 0.1-6.0 mg/kg for 3 of every 4 weeks (Regimen A) or once every 3 weeks (10-18 mg/kg) (Regimen B). Results Sixty-six patients received margetuximab (34 patients for Regimen A and 32 patients for Regimen B). The MTD was not reached for either regimen. Treatment was well-tolerated, with mostly Grade 1 and 2 toxicities consisting of constitutional symptoms such as pyrexia, nausea, anemia, diarrhea, and fatigue. Among 60 response-evaluable patients, confirmed partial responses and stable disease were observed in 7 (12%) and 30 (50%) patients, respectively; 26 (70%) of these patients had received prior HER2-targeted therapy. Tumor reductions were observed in over half (18/23, 78%) of response-evaluable patients with breast cancer including durable (>30 weeks) responders. Ex vivo analyses of patient peripheral blood mononuclear cell samples confirmed the ability of margetuximab to support enhanced ADCC compared with trastuzumab. Conclusions Margetuximab was well-tolerated and has promising single-agent activity. Further development efforts of margetuximab as single agent and in combination with other therapeutic agents are ongoing. Trial Registration ID NCT01148849.
Collapse
Affiliation(s)
- Y J Bang
- Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - G Giaccone
- Department of Medical Oncology, National Cancer Institute, Bethesda, MD, USA
| | - S A Im
- Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - D Y Oh
- Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - T M Bauer
- Department of Drug Development, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA
| | | | - H Li
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - G R Chichili
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - P A Moore
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - S Hong
- MacroGenics, Inc, Rockville, Maryland 20850, USA
| | - S J Stewart
- Departamento de Física, Facultad de Ciencias Exactas, UNLP, IFLP-CONICET C.C.No. 67, 1900 La Plata, Argentina
| | | | | | - H A Burris
- Department of Drug Development, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA
| |
Collapse
|
23
|
Burris HA, Chan A, Campone M, Blackwell KL, Winer EP, Janni W, Verma S, Burdaeva O, Alba E, Favret AM, Mondal S, Miller M, Germa C, Hirawat S, Yap YS. Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with ABC who present with visceral metastases have a worse outcome than patients with non-visceral disease, while patients with bone-only disease tend to have a better prognosis. Ribociclib (LEE011) is an oral, selective inhibitor of cyclin-dependent kinase (CDK) 4/6. In a Phase 3, placebo-controlled, randomized trial (MONALEESA-2; NCT01958021), first-line ribociclib (R) + letrozole (L) significantly prolonged progression-free survival (PFS) vs placebo (P) + L in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) ABC, with a hazard ratio of 0.556 (95% confidence interval [CI]: 0.429–0.720; p=0.00000329) at the interim analysis cut-off date (Jan 29, 2016). Here, we present subgroup analyses in patients with visceral metastases, and those with bone-only disease.
Methods: Postmenopausal women with HR+, HER2– ABC were randomized 1:1 to receive R (600 mg/day; 3-weeks-on/1-week-off) + L (2.5 mg/day; continuous) or P+L, stratified by the presence of liver and/or lung metastases. No prior CDK4/6 inhibitors or systemic therapy for ABC were allowed. Eligible patients had Eastern Cooperative Oncology Group performance status ≤1, baseline alanine/aspartate aminotransferase levels <5× upper limit of normal (ULN) or <2.5× ULN for patients with or without liver metastases, respectively, and ≥1 predominantly lytic bone lesion at baseline for patients with bone-only disease. Locally assessed PFS was analyzed for all patients (primary endpoint), and for predefined patient subgroups.
Results: Overall, 668 patients were randomized; 393 had visceral metastases and 147 had bone-only disease.
Visceral metastasesBone-only disease n=393n=147 R+LP+LR+LP+L n=197n=196n=69n=78Median age, years (range)63 (23–91)63 (29–88)65 (37–85)63 (37–84)De novo metastatic disease, n (%)53 (27)55 (28)28 (41)24 (31)Non-de novo disease-free interval, n (%)≤24 months12 (6)15 (8)5 (7)6 (8)>24 months132 (67)126 (64)36 (52)48 (62)Discontinued treatment, n (%)83 (42)111 (57)29 (42)40 (51)Reason for discontinuation, n (%)Disease progression56 (28)93 (47)17 (25)31 (40)Patient/physician decision10 (5)15 (8)7 (10)6 (8)Adverse events16 (8)3 (2)4 (6)2 (3)Protocol deviation001 (1)1 (1)Death1 (<1)000
In patients with visceral metastases: Median PFS was not reached in the R+L arm (95% CI: 19.3–not estimable [NE]) vs 13.0 months (95% CI: 12.6 –16.5) in the P+L arm, with hazard ratio 0.535 (95% CI: 0.385–0.742). Median duration of exposure was 12.0 and 13.0 months (R and L, respectively) in the R+L arm, and 12.1 and 12.2 months (P and L, respectively) in the P+L arm.
In patients with bone-only disease: Median PFS was not reached in the R+L arm (95% CI: NE–NE) vs 15.3 months (95% CI: 13.8–NE) in the P+L arm, with hazard ratio 0.690 (95% CI: 0.381–1.249). Median duration of exposure was 12.1 and 12.6 months (R and L, respectively) in the R+L arm, and 12.7 and 12.9 months (P and L, respectively) in the P+L arm.
Conclusions: First-line R+L was well tolerated and significantly prolonged PFS vs P+L in postmenopausal women with HR+, HER2– ABC, both in patients with visceral metastases and those with bone-only disease.
Keywords: Advanced breast cancer; CDK4/6 inhibitor; Letrozole; Ribociclib
Citation Format: Burris HA, Chan A, Campone M, Blackwell KL, Winer EP, Janni W, Verma S, Burdaeva O, Alba E, Favret AM, Mondal S, Miller M, Germa C, Hirawat S, Yap YS. First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-16.
Collapse
Affiliation(s)
- HA Burris
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - A Chan
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - M Campone
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - KL Blackwell
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - EP Winer
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - W Janni
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - S Verma
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - O Burdaeva
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - E Alba
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - AM Favret
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - S Mondal
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - M Miller
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - C Germa
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - S Hirawat
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| | - YS Yap
- Sarah Cannon Research Institute, Nashville, TN; Breast Cancer Research Centre WA & Curtin University, Perth, Australia; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nantes, France; Duke University Medical Center, Durham, NC; Dana-Farber Cancer Institute, Boston, MA; Universitätsklinikum Ulm, Ulm, Germany; Tom Baker Cancer Centre, Calgary, Canada; Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Virginia Cancer Specialists, Arlington, VA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; National Cancer Center Singapore, Singapore
| |
Collapse
|
24
|
Yardley D, Hurvitz S, Jiang ZF, Toi M, Burris H, Buyse M, Slamon D, Makhson A, Elsaid A, Lerzo G, Hellerstedt B, Nuzzo F, Sohn J, Manzyuk L, Cabaribere D, Lincy J, Weimann A, Noel-Baron F, Pacaud L, Andre F. Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-13] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Everolimus (EVE), an mTOR inhibitor has shown activity in HER2+ advanced breast cancer (ABC) in both preclinical and clinical studies. In the pivotal BOLERO-1 trial (NCT00876395), the progression-free survival (PFS) was not significantly different between the EVE + trastuzumab (TRAS) + paclitaxel (PAC) combination and placebo (PBO) + TRAS + PAC in the full HER2+ population (EVE, 15.0 mo vs PBO, 14.5 mo; HR=0.89; 95% CI: 0.73-1.08; p=0.1166). Although not reaching protocol defined level for statistical significance, the hormone receptor negative (HR-) subpopulation appeared to benefit from EVE, with a 7.2 mo PFS benefit vs PBO arm (EVE, 20.3 mo vs PBO, 13.1 mo; HR=0.66; 95% CI: 0.48-0.91; p=0.0049). The final exploratory overall survival (OS) analysis from the study is presented here.
Methods
In this phase 3 randomized trial, 719 women with HER2+ ABC without prior TRAS or chemotherapy in the metastatic setting were randomized 2:1 to receive either EVE (10 mg/d) or placebo (PBO) and weekly PAC+TRAS, stratified by visceral metastasis (lung, liver, peritoneal or pleural: yes vs no) and prior adjuvant or neo-adjuvant treatment with TRAS (yes vs no). As the primary objectives (PFS on full population and on HR- subpopulation) of BOLERO-1 were not met, the key secondary endpoint of OS was not formally statistically tested. However, given the results of PFS, in particular in the HR- subpopulation, a change to the OS analysis plan was made by introducing one final exploratory OS analysis at the time of study termination.
Results
At data cutoff (Dec 31, 2015), the median duration of exposure was 40.8 weeks (range: 0.6-320.4) in the EVE arm and 48.1 weeks (range: 1.1-308.0) in the PBO arm. After a median follow-up of 60.3 mo, 350 deaths were recorded in the full population, 238 (49.6%) in the EVE arm and 112 (46.9%) pts in the PBO arm. In the full population, the median OS was comparable in the EVE vs PBO arms (48.6 mo vs 50.0 mo respectively; HR = 1.13; 95% CI: 0.90-1.42). In the HR- subpopulation, 138 deaths were recorded; 88 (42.3%) pts in the EVE arm and 50 (48.5%) pts in the PBO arm. In the HR- subpopulation, the median OS in the EVE arm was longer compared to PBO arm (57.0 mo vs 41.6 mo respectively; HR = 0.83; 95% CI: 0.59-1.18). Stomatitis, diarrhea, alopecia, cough, rash, pyrexia, neutropenia, and fatigue were the most frequent adverse events (AEs) reported in EVE arm (≥35%). AEs leading to dose interruption and/or change were reported in 441 (93.4%) pts in EVE arm and 165 (69.3%) pts in the PBO arm respectively. Overall, AEs leading to treatment discontinuation were reported in 262 (55.5%) pts in EVE arm and 98 (41.2%) pts in PBO arm. Serious AEs were reported in 171 (36.2%) pts in the EVE arm and 40 (16.8%) pts in the PBO arm respectively. On treatment AE related deaths were reported for 3.6% pts in the EVE arm and 0% pts in the PBO arm.
Conclusions
The median OS was similar in the EVE vs PBO arms for overall population. However, a prolongation of 15.4 mo in median OS of HR- subpopulation was observed in the EVE arm vs PBO arm in this exploratory analysis. Pts in the EVE arm had a manageable safety, consistent with the safety profile of EVE and no new safety signals were identified.
Citation Format: Yardley D, Hurvitz S, Jiang Z-f, Toi M, Burris H, Buyse M, Slamon D, Makhson A, Elsaid A, Lerzo G, Hellerstedt B, Nuzzo F, Sohn J, Manzyuk L, Cabaribere D, Lincy J, Weimann A, Noel-Baron F, Pacaud L, Andre F. Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1 [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-13.
Collapse
Affiliation(s)
- D Yardley
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - S Hurvitz
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - Z-f Jiang
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - M Toi
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - H Burris
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - M Buyse
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - D Slamon
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - A Makhson
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - A Elsaid
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - G Lerzo
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - B Hellerstedt
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - F Nuzzo
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - J Sohn
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - L Manzyuk
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - D Cabaribere
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - J Lincy
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - A Weimann
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - F Noel-Baron
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - L Pacaud
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - F Andre
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; University of California, Los Angeles (UCLA), Los Angeles, CA; Beijing 307 Hospital of PLA, Beijing, China; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Sarah Cannon Research Institute, Nashville, TN; International Drug Development Institute (IDDI), Louvain La Neuve, Belgium; University of California, Los Angeles (UCLA), Angeles, CA; Moscow Municipal Hospital No. 62, Moscow, Russian Federation; Clinical Research Centre, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Sanatorio de la Providencia, Buenos aires, Argentina; Texas Oncology, Austin, TX; IRCCS Fondazione G. Pascale, Dipartimento di Senologia, Napoli, Italy; Severance Hospital, Yonsei University Health System, Seoul, Korea; Russian Cancer Research Centre, Moscow, Russian Federation; Translational Research in Oncology (TRIO), Paris, France; Novartis Pharma AG, Basel, Switzerland; Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| |
Collapse
|
25
|
Yardley DA, Blakely L, Hemphill B, Joseph M, Liggett W, Daniel B, Castrellon A, Shastry M, Finney L, DeBusk L, Hainsworth JD, Burris HA. Abstract P4-22-09: A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Therapies targeting estrogen receptor (ER) signaling are standard for patients (pts) with hormone receptor positive (HR+) (ER and/or progesterone receptor [PR] positive) metastatic breast cancer (MBC). Dysregulation of the mammalian target of rapamycin (mTOR) pathway has been associated with endocrine therapy (ET) resistance. BOLERO-2 demonstrated that the addition of the mTOR inhibitor, everolimus (EVE), to exemestane doubled the PFS in HR+ HER2- MBC pts who previously progressed on nonsteroidal aromatase inhibitor therapy.The premise of this phase 2 trial in HR+ MBC is that the addition of EVE to the last ET on which the disease progressed may restore sensitivity to ET and extend the benefit of the anti-estrogen therapy.
Methods: Pts ≥18 yrs with HR+, HER2- unresectable, locally recurrent, or MBC refractory to ET in either the adjuvant or advanced/metastatic setting. 0-1 chemotherapy (chemo) regimens for MBC were permitted. Post-/ pre-/peri-menopausal women were eligible with ovarian function suppression permitted. Additional eligibility requirements include: no prior mTOR inhibitor therapy, measurable or evaluable disease, ECOG ≤2, adequate bone marrow and organ function. EVE (10 mg PO daily) was administered on a 4-wk cycle in combination with the same dose and schedule of the last ET to which their disease became resistant. Disease assessments were performed every 2 cycles and treatment continued until disease progression or unacceptable toxicity. Blood samples and archival tumor were collected respectively for the VeriStrat Assay and for the Foundation One molecular profiling platform.
Results: 48 pts were enrolled; data from 26 pts is presented. Median age 63.5 yrs (range, 36-81) with 46% ≥ 65 yrs. 14 (54%) pts had received chemo in the adjuvant setting, 9 pts (35%) received chemo for MBC, and 4 pts (15%) received chemo in both settings. All pts had at least 1 prior hormonal therapy; 9 pts received ≥ 3 hormonal agents. EVE was combined with tamoxifen (27%), AIs (61%), and fulvestrant (12%). Median time on treatment was 18.6 wks (range 1-48.9 weeks). 5 pts (19%) remain on treatment and 21 (81%) have discontinued therapy due to: disease progression - 17, toxicity -2, and other causes - 2. 23 pts were evaluable for response. 1 pt on fulvestrant plus EVE had a PR and 18 pts (78%) had SD as best response, with SD > 6 mos in 7 pts, for a clinical benefit rate (CR+PR+ SD ≥ 6 months) of 35%. With a median follow up of 11 mos (range 2-16 mos), the median PFS was 6.6 months (range 3.6-9.4); the median OS has not been reached. Treatment-related adverse events consisted mostly of stomatitis, rash and fatigue with few G3 events: stomatitis 3 pts, rash 2 pts, and 1 each of fatigue, edema, and neutropenia. G1 pneumonitis was present in 2 pts. There were no G4 events or treatment related deaths.
Conclusions: In HR+ HER2- advanced/MBC patients who progressed on prior ET, the addition of EVE to the ET to which their disease became resistant, resulted in 1 PR and 7 pts with SD > 6 mos. The results of the full study population will be presented. Modulation of the mTOR/AKT/PI3K pathway with EVE may extend the benefit of ET, even after tumor progression on ET alone.
Citation Format: Yardley DA, Blakely L, Hemphill B, Joseph M, Liggett W, Daniel B, Castrellon A, Shastry M, Finney L, DeBusk L, Hainsworth JD, Burris III HA. A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-09.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - L Blakely
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - B Hemphill
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - M Joseph
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - W Liggett
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - B Daniel
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - A Castrellon
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - M Shastry
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - L Finney
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - L DeBusk
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - JD Hainsworth
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| | - HA Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Chattanooga, TN; Memorial Cancer Institute, Hollywood, FL; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
26
|
Forero-Torres A, Modi S, Specht J, Miller K, Weise A, Burris H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-12-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
LIV-1, a transmembrane protein and downstream target of STAT3, is highly expressed in breast cancer cells. It is associated with lymph node involvement and metastatic progression. SGN-LIV1A is an anti-LIV-1 antibody conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE). Upon binding to cell-surface LIV-1, SGN-LIV1A is internalized and releases MMAE, which binds to tubulin and induces G2/M arrest and apoptosis.
Methods
This is an ongoing, phase 1 dose-escalation study evaluating safety, tolerability, pharmacokinetics, and antitumor activity of SGN-LIV1A (q3 wks IV) in women with LIV-1-positive, unresectable, locally advanced or metastatic breast cancer (LA/MBC) (NCT01969643). Patients (pts) with measurable disease and ≥2 prior cytotoxic regimens for LA/MBC were eligible. Pts with ≥Grade 2 neuropathy were excluded. Response was assessed per RECIST v1.1; pts with stable disease (SD) or better could continue treatment until disease progression or intolerable toxicity. At completion of dose escalation in hormone receptor-positive/HER2-negative (HR+/HER2–) and triple-negative (TN) pts, expansion cohorts were opened to further evaluate safety and antitumor activity of monotherapy in TN pts and combination therapy with trastuzumab (Tz) in HER2-positive (HER2+) pts. Pre- and post-treatment tumor biopsies were done to evaluate LIV-1 expression and other correlative endpoints.
Results
To date, 39 pts (18 HR+/HER2–, 21 TN) have received a median of 3 cycles (range, 1–10) of SGN-LIV1A monotherapy at doses of 0.5–2.8 mg/kg. Median age was 57 yrs (range, 33–79). At baseline, pts had a median of 4 prior cytotoxic regimens for LA/MBC (range, 2–8); 36 had visceral disease and 25 had bone involvement. No dose-limiting toxicities (DLT) occurred in 19 DLT-evaluable pts; maximum tolerated dose was not exceeded at 2.8 mg/kg. Treatment-emergent adverse events (AEs) reported in ≥30% of pts were: fatigue (64%), nausea (54%), alopecia (46%), decreased appetite (41%), constipation (39%), neutropenia (33%), and vomiting (31%). Peripheral neuropathy was reported in 9 pts (23%). Most AEs were Grade 1/2, except neutropenia (all ≥Grade 3). Four pts discontinued treatment due to AEs (acute respiratory distress syndrome, nausea, pneumonia, tachycardia). In dose escalation, modest activity was observed in 17 efficacy evaluable (EE) HR+/HER2- pts, with a disease control rate (DCR) of 59% (10 SD), including 1 pt with SD≥24 wks. Among the 17 EE TN pts (dose escalation plus cohort expansion), the overall response rate (ORR) was 41% (7 PR), DCR was 82% (7 PR, 7 SD) and clinical benefit rate (CBR=OR+SD≥24 wks) was 53% (9 pts). For TN pts, median PFS was 17.1 wks (95% CI: 6.0, 18.4); 6 pts remain on treatment.
Of 281 MBC tumor samples evaluated for LIV-1, 93% were positive; 81% had moderate-to-high expression (H-score ≥100).
Conclusions
LIV-1 is expressed in almost all MBC tumors. SGN-LIV1A monotherapy has been generally well tolerated and shown encouraging antitumor activity in heavily pretreated TN MBC, with a PR rate of 41% and a CBR at ≥24 wks of 53%. Response duration data continue to evolve. Enrollment continues in the TN monotherapy expansion cohort and the HER2+ combination cohort with Tz.
Citation Format: Forero-Torres A, Modi S, Specht J, Miller K, Weise A, Burris III H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-12-04.
Collapse
Affiliation(s)
- A Forero-Torres
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - S Modi
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - J Specht
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - K Miller
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - A Weise
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - H Burris
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - M Liu
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - I Krop
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - L Pusztai
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - A Kostic
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - M Li
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| | - M Mita
- University of Alabama at Birmingham, Birmingham, AL; Memorial Sloan Kettering Cancer Center, New York, NY; Seattle Cancer Care Alliance, University of Washington, Seattle, WA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Karmanos Cancer Institute, Detroit, MI; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; Yale University School of Medicine, New Haven, CT; Seattle Genetics, Inc., Bothell, WA; Cedars-Sinai Medical Center, Los Angeles, CA
| |
Collapse
|
27
|
Yardley DA, Peacock N, Young RR, Silber A, Chung G, Webb CD, Jones SF, Shastry M, Midha R, DeBusk LM, Hainsworth JD, Burris HA. Abstract P5-14-04: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The frequency of AR expression varies in the different breast cancer subtypes with 88%, 59%, and 32% expression reported in ER+, HER2+, and triple negative tumors, respectively. AR expression is associated with resistance to endocrine therapy in ER+ breast cancer. Androgen levels frequently increase following treatment with aromatase inhibitors suggesting a role for androgen synthesis inhibitors in ER+ breast cancer. AR signaling and expression are seen in triple negative breast cancer (TNBC), and a distinct AR TNBC subtype can be identified by gene expression profiling. AR expression in TNBC offers a potential therapeutic target. Preclinical and clinical studies demonstrated anti-androgen agent activity in breast cancer cell lines; preliminary clinical data suggests activity in TNBC. Orteronel is a novel, oral, selective, nonsteroidal inhibitor of 17, 20-lyase, a key enzyme in androgen biosynthesis that is being evaluated as endocrine therapy in various hormone-sensitive cancers. In this phase 2 study we are evaluating single agent orteronel in AR+ MBC.
Methods: Pts with AR expressing MBC (≥10% staining by central immunohistochemistry) were eligible. Pts were grouped into 2 cohorts for analysis: Cohort 1-TNBC and Cohort 2-ER+ (HER2 could be +/- in this cohort). Pts must have been previously treated with standard therapy for MBC (1-3 chemotherapy regimens for TNBC, 1-3 hormonal therapies + 1 chemotherapy for ER+ patients, ≥2 HER2-targeted regimens for HER2+ patients). A 6 pt lead-in for safety and tolerability of orteronel in AR+ female MBC pts was followed by open enrollment to either cohort. All pts received 300 mg orteronel PO BID over a 4 week cycle and underwent response assessment every 2 cycles. Treatment was continued until disease progression or unacceptable toxicity. The hypothesized response rate for Cohort 1 was 10% and 13% for Cohort 2. We present the results of a protocol-specified interim analysis of the ER+ MBC pts (Cohort 2).
Results: From 3/2014 to 4/2015, a total of 29 pts were enrolled on cohort 2. Median age was 65 years (range, 39-79); 90% ECOG ≤1; 90% HER2-/10% HER2+; median of 7 prior therapies (range 3-11). 93% had prior chemotherapy. Pts received a median of 2 cycles of orteronel treatment (range 1-4) and 3 pts (10%) are still on treatment. Of the 26 pts (90%) pts that have discontinued, 19 (66%) discontinued due to disease progression, 4 (14%) due to pt decision, 2 (7%) due to adverse event (AE), and 1 (3%) due to non-compliance. The most common treatment-related G 3/4 AEs were increased lipase [3 pts (10%)] and hypertension [2 pts (7%)]. There were no treatment-related SAEs or deaths on study. Three pts (10%) had stable disease as their best response. Further response evaluation is underway.
Conclusions: Orteronel monotherapy was well tolerated but appears to have limited single-agent activity in this heavily pre-treated ER+ MBC pt population. The full results from this interim analysis will be presented.
Citation Format: Yardley DA, Peacock N, Young RR, Silber A, Chung G, Webb CD, Jones SF, Shastry M, Midha R, DeBusk LM, Hainsworth JD, Burris HA. A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer: Interim analysis. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-14-04.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - N Peacock
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - RR Young
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - A Silber
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - G Chung
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - CD Webb
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - SF Jones
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - M Shastry
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - R Midha
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - LM DeBusk
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - JD Hainsworth
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| | - HA Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX; Yale School of Medicine, New Haven, CT; Baptist Health Louisville, Louisville, KY; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
28
|
Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. Statistical controversies in clinical research: statistical significance-too much of a good thing …. Ann Oncol 2016; 27:760-2. [PMID: 26861602 DOI: 10.1093/annonc/mdw047] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 01/26/2016] [Indexed: 11/14/2022] Open
Abstract
The use and interpretation of P values is a matter of debate in applied research. We argue that P values are useful as a pragmatic guide to interpret the results of a clinical trial, not as a strict binary boundary that separates real treatment effects from lack thereof. We illustrate our point using the result of BOLERO-1, a randomized, double-blind trial evaluating the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line therapy for HER2+ advanced breast cancer. In this trial, the benefit of everolimus was seen only in the predefined subset of patients with hormone receptor-negative breast cancer at baseline (progression-free survival hazard ratio = 0.66, P = 0.0049). A strict interpretation of this finding, based on complex 'alpha splitting' rules to assess statistical significance, led to the conclusion that the benefit of everolimus was not statistically significant either overall or in the subset. We contend that this interpretation does not do justice to the data, and we argue that the benefit of everolimus in hormone receptor-negative breast cancer is both statistically compelling and clinically relevant.
Collapse
Affiliation(s)
- M Buyse
- Department of Biostatistics, International Drug Development Institute (IDDI), Louvain La Neuve, Belgium
| | - S A Hurvitz
- Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, USA
| | - F Andre
- Department of Medical Oncology, Institut Gustave Roussy, Université Paris Sud, Villejuif, France
| | - Z Jiang
- Department of Breast Oncology, Beijing 307 Hospital of PLA, Beijing, China
| | - H A Burris
- Department of Drug Development, Sarah Cannon Research Institute, Nashville, USA
| | - M Toi
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - W Eiermann
- Breast Surgery Clinic, Isarklinikum München, Munich, Germany
| | - M-A Lindsay
- Department of Scientific Development, Translational Research in Oncology (TRIO), Edmonton, Canada
| | - D Slamon
- Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, USA
| |
Collapse
|
29
|
Arkenau H, Voskoboynik M, Infante J, Brenner A, Patel M, Borazanci E, Falchook G, Molife L, Pant S, Dean E, Pelosof L, Jones S, Rubino C, McCulloch W, Zhukova-Harrill V, Kemble G, O'Farrell M, Burris H. 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30076-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Ann Oncol 2015; 26:804-811. [PMID: 25573533 DOI: 10.1093/annonc/mdu581] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Olaparib (Lynparza) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that induces synthetic lethality in cancers with homologous recombination defects. PATIENTS AND METHODS In this phase I, dose-escalation trial, patients with advanced solid tumours received olaparib (50-200 mg capsules b.i.d.) continuously or intermittently (days 1-14, per 28-day cycle) plus gemcitabine [i.v. 600-800 mg/m(2); days 1, 8, 15, and 22 (cycle 1), days 1, 8, and 15 (subsequent cycles)] to establish the maximum tolerated dose. A separate dose-escalation phase evaluated olaparib in tablet formulation (100 mg o.d./b.i.d.; days 1-14) plus gemcitabine (600 mg/m(2)). In an expansion phase, patients with genetically unselected locally advanced or metastatic pancreatic cancer were randomised 2 : 1 to the tolerated olaparib capsule combination dose or gemcitabine alone (1000 mg/m(2)). RESULTS Sixty-six patients were treated [dose-escalation phase, n = 44 (tablet cohort, n = 12); dose-expansion phase, n = 22 (olaparib plus gemcitabine, n = 15; gemcitabine alone, n = 7)]. In the dose-escalation phase, four patients (6%) experienced dose-limiting toxicities (raised alanine aminotransferase, n = 2; neutropenia, n = 1; febrile neutropenia, n = 1). Grade ≥3 adverse events were reported in 38/47 patients (81%) treated with olaparib capsules plus gemcitabine; most common were haematological toxicities (55%). Tolerated combinations were olaparib 100 mg b.i.d. capsule (intermittently, days 1-14) plus gemcitabine 600 mg/m(2) and olaparib 100 mg o.d. tablet (intermittently, days 1-14) plus gemcitabine 600 mg/m(2). There were no differences in efficacy observed during the dose-expansion phase. CONCLUSIONS Olaparib 100 mg b.i.d. (intermittent dosing; capsules) plus gemcitabine 600 mg/m(2) is tolerated in advanced solid tumour patients, with no unmanageable/unexpected toxicities. Continuous dosing of olaparib or combination with gemcitabine at doses >600 mg/m(2) was not considered to have an acceptable tolerability profile for further study. CLINICALTRIALSGOV NCT00515866.
Collapse
Affiliation(s)
- J Bendell
- Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville.
| | - E M O'Reilly
- Memorial Sloan Kettering Cancer Center, New York, USA
| | - M R Middleton
- Department of Oncology, University of Oxford, Oxford
| | - I Chau
- Department of Medicine, Royal Marsden Hospital, Sutton, UK
| | - H Hochster
- Yale Cancer Center, Yale School of Medicine, New Haven, USA
| | - A Fielding
- Global Medicines Development, AstraZeneca
| | - W Burke
- Clinical Pharmacology, AstraZeneca, Macclesfield, UK
| | - H Burris
- Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, Nashville
| |
Collapse
|
31
|
Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, Patnaik A, Jones SF, Rasco D, Cox DS, Durante M, Bellew KM, Park J, Le NT, Infante JR. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol 2015; 26:58-64. [PMID: 25344362 DOI: 10.1093/annonc/mdu482] [Citation(s) in RCA: 96] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND This phase Ib trial investigated the safety, tolerability, and recommended phase II dose and schedule of the MEK inhibitor trametinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus. Secondary objectives included pharmacokinetic (PK) characterization and evaluation of clinical activity. PATIENTS AND METHODS A total of 67 patients with advanced solid tumors were enrolled in this open-label, single-arm, dose-escalation study. Dose escalation followed a 3 + 3 design. Patients were assigned to one of 10 different cohorts, involving either daily dosing with both agents or daily dosing with trametinib and intermittent everolimus dosing. This included an expansion cohort comprising patients with pancreatic tumors. PKs samples were collected predose, as well as 1, 2, 4, and 6 h post-dose on day 15 of the first treatment cycle. RESULTS Concurrent treatment with trametinib and everolimus resulted in frequent treatment-related adverse events, including mucosal inflammation (40%), stomatitis (25%), fatigue (54%), and diarrhea (42%). PK assessment did not suggest drug-drug interactions between these two agents. Of the 67 enrolled patients, 5 (7%) achieved partial response (PR) to treatment and 21 (31%) displayed stable disease (SD). Among the 21 patients with pancreatic cancer, PR was observed in 1 patient (5%) and SD in 6 patients (29%). CONCLUSIONS This study was unable to identify a recommended phase II dose and schedule of trametinib in combination with everolimus that provided an acceptable tolerability and adequate drug exposure.
Collapse
Affiliation(s)
- A W Tolcher
- South Texas Accelerated Research Therapeutics LLC, San Antonio.
| | - J C Bendell
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | | | - H A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - A Patnaik
- South Texas Accelerated Research Therapeutics LLC, San Antonio
| | - S F Jones
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | - D Rasco
- South Texas Accelerated Research Therapeutics LLC, San Antonio
| | - D S Cox
- GlaxoSmithKline, Collegeville
| | | | - K M Bellew
- Pharmaceutical Companies of Johnson and Johnson, Greater Philadelphia Area
| | - J Park
- GlaxoSmithKline, Collegeville
| | - N T Le
- Novartis, East Hanover, USA
| | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
32
|
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 2014; 25:2357-2362. [PMID: 25231953 PMCID: PMC6267855 DOI: 10.1093/annonc/mdu456] [Citation(s) in RCA: 386] [Impact Index Per Article: 38.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 08/27/2014] [Accepted: 09/09/2014] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR(+)), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analysis is presented here. PATIENTS AND METHODS BOLERO-2 is a phase III, double-blind, randomized international trial comparing EVE 10 mg/day plus EXE 25 mg/day versus placebo (PBO) + EXE 25 mg/day in postmenopausal women with HR(+) advanced breast cancer with prior exposure to NSAIs. The primary end point was PFS by local investigator assessment; OS was a key secondary end point. RESULTS At the time of data cutoff (3 October 2013), 410 deaths had occurred and 13 patients remained on treatment. Median OS in patients receiving EVE + EXE was 31.0 months [95% confidence interval (CI) 28.0-34.6 months] compared with 26.6 months (95% CI 22.6-33.1 months) in patients receiving PBO + EXE (hazard ratio = 0.89; 95% CI 0.73-1.10; log-rank P = 0.14). Poststudy treatments were received by 84% of patients in the EVE + EXE arm versus 90% of patients in the PBO + EXE arm. Types of poststudy therapies were balanced across arms, except for chemotherapy (53% EVE + EXE versus 63% PBO + EXE). No new safety concerns were identified. CONCLUSIONS In BOLERO-2, adding EVE to EXE did not confer a statistically significant improvement in the secondary end point OS despite producing a clinically meaningful and statistically significant improvement in the primary end point, PFS (4.6-months prolongation in median PFS; P < 0.0001). Ongoing translational research should further refine the benefit of mTOR inhibition and related pathways in this treatment setting. TRIAL REGISTRATION NUMBER NCT00863655.
Collapse
Affiliation(s)
- M Piccart
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
| | - G N Hortobagyi
- Department of Breast Medical Oncology, Multidisciplinary Breast Cancer Research Program, University of Texas MD Anderson Cancer Center, Houston, USA
| | - M Campone
- Institut de Cancérologie de l'Ouest, René Gauducheau, Centre de Recherche en Cancérologie, Nantes Saint Herblain, France
| | - K I Pritchard
- Department of Medicine, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada
| | - F Lebrun
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Y Ito
- Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
| | - S Noguchi
- Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - A Perez
- Breast Cancer Centers, Memorial Cancer Institute, Hollywood
| | - H S Rugo
- Breast Oncology and Clinical Trials Education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - I Deleu
- Oncologic Centre, AZ Nikolaas, Sint-Niklaas, Belgium
| | - H A Burris
- Sarah Cannon Research Institute, Nashville, USA
| | - L Provencher
- Centre des Maladies du Sein Deschênes-Fabia, CHU-Hôpital du Saint Sacrement, Québec, Canada
| | - P Neven
- Multidisciplinary Breast Centre and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium
| | - M Gnant
- Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | | | - C Wu
- Novartis Pharmaceuticals Corporation, East Hanover
| | - J Fan
- Novartis Pharmaceuticals Corporation, East Hanover
| | - W Feng
- Novartis Pharmaceuticals Corporation, East Hanover
| | - T Taran
- Novartis Pharmaceuticals Corporation, East Hanover
| | - J Baselga
- Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
33
|
Juric D, Burris H, Schuler M, Schellens J, Berlin J, Seggewiß-Bernhardt R, Gil-Martin M, Gupta A, Rodon J, Tabernero J, Janku F, Rugo H, Bootle D, Quadt C, Coughlin C, Demanse D, Blumenstein L, Baselga J. Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.11] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Rini B, Redman B, Garcia JA, Burris HA, Li S, Fandi A, Beck R, Jungnelius U, Infante JR. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol 2014; 25:1794-1799. [PMID: 24914044 PMCID: PMC4311191 DOI: 10.1093/annonc/mdu212] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Revised: 05/27/2014] [Accepted: 06/02/2014] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide plus sunitinib in metastatic renal cell carcinoma (RCC) patients. PATIENTS AND METHODS Patients with histologically confirmed, metastatic RCC were treated with 10 mg/day lenalidomide plus 37.5 mg/day sunitinib, orally in 21-day cycles. Doses were escalated to determine the MTD in phase I, with additional patients planned at this dose in phase II. Primary end points were MTD and response rate. RESULTS Sixteen patients received a median of 2, 3, and 5 cycles in cohort 1 [lenalidomide 10 mg (days 1-21) and sunitinib 37.5 mg (days 1-21)], cohort 2 [lenalidomide 10 mg (days 1-21) and sunitinib 37.5 mg (days 1-14)], and cohort 3 [lenalidomide 15 mg (days 1-21) and sunitinib 37.5 mg (days 1-14)], respectively. Median treatment durations were 41, 63, and 97 days for lenalidomide; and 41, 57, and 97.5 days for sunitinib. The MTD was found to be continuous dosing of lenalidomide 10 mg/day plus sunitinib 37.5 mg/day for 14 of 21 days. Dose-limiting toxicities included neutropenia, leukopenia, thrombocytopenia, asthenia, atrial fibrillation, and increased transaminases. The most frequent grade 3-4 treatment-emergent adverse events were hematologic, including neutropenia and leukopenia. One patient achieved partial response, and seven had stable disease of which three were confirmed at subsequent tumor assessments. B cells and several T-cell subsets were modulated versus baseline. CONCLUSION The dose schedules of lenalidomide and sunitinib evaluated in this study were not well tolerated; cumulative toxicity precluded enrollment at the MTD.
Collapse
Affiliation(s)
- B Rini
- Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland.
| | - B Redman
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor
| | - J A Garcia
- Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, Cleveland
| | - H A Burris
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| | | | | | | | | | - J R Infante
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville
| |
Collapse
|
35
|
Bellmunt J, Petrylak D, Powles T, Braiteh F, Vogelzang N, Cruz C, Burris H, Eder J, Fine G, Teng M, Shen X, Bruey J, Boyd Z, Hegde P, Chen D, Loriot Y. Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Kristeleit R, Shapira-Frommer R, Burris H, Patel M, Lorusso P, Oza A, Balmaña J, Domchek S, Chen L, Montes A, Plummer R, Arkenau H, Maloney L, Dominy E, Shapiro G. Phase 1/2 Study of Oral Rucaparib: Updated Phase 1 and Preliminary Phase 2 Results. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P, Baker AF, Raghunand N, Crowley J, Von Hoff DD. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 2014; 74:379-87. [PMID: 24939212 DOI: 10.1007/s00280-014-2499-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2014] [Accepted: 05/24/2014] [Indexed: 02/06/2023]
Abstract
PURPOSE Vatalanib (PTK 787/ZK22584) is an oral poly-tyrosine kinase inhibitor with strong affinity for platelet-derived growth factor and vascular endothelial growth factor (VEGF) receptors. We conducted an open-label, phase II multicenter therapeutic trial investigating the efficacy and tolerability of vatalanib in patients with metastatic or advanced pancreatic cancer who failed first-line gemcitabine-based therapy. METHODS Vatalanib treatment consisted of a twice daily oral dosing using a "ramp-up schedule," beginning with 250 mg bid during week 1,500 mg bid during week 2, and 750 mg bid on week three and thereafter. The primary objective of this study was to evaluate the 6-month survival rate. RESULTS Sixty-seven patients were enrolled. The median age was 64, and 66% (N = 43) had only one prior regimen. Common grade 3/4 adverse events included hypertension (20%; N = 13), fatigue (17%; N = 11), abdominal pain (17%; N = 11), and elevated alkaline phosphatase (15%; N = 10). Among the 65 evaluable patients, the 6-month survival rate was 29% (95% CI 18-41%) and the median progression-free survival was 2 months. Fifteen patients survived 6 months or more. Two patients had objective partial responses, and 28% of patients had stable disease. Changes in biomarkers including soluble VEGF and vascular endothelial growth factor receptor did not correlate with response to drug. CONCLUSION Vatalanib was well tolerated as a second-line therapy and resulted in favorable 6-month survival rate in patients with metastatic pancreatic cancer, compared with historic controls.
Collapse
Affiliation(s)
- T Dragovich
- Banner MD Anderson Cancer Center, 1900 N. Higley Road, Gilbert, AZ, 85234, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Crown J, Kennedy MJ, Tresca P, Marty M, Espie M, Burris HA, DeSilvio M, Lau MR, Kothari D, Koch KM, Diéras V. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol 2014; 24:2005-11. [PMID: 23878115 DOI: 10.1093/annonc/mdt222] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND This phase IB, open-label, dose-escalation study evaluated the safety, tolerability, and optimally tolerated regimen (OTR) of lapatinib in combination with docetaxel and trastuzumab in patients with previously untreated stage IV metastatic breast cancer (MBC) tumors overexpressing human epidermal growth factor receptor 2 (HER2). PATIENTS AND METHODS Evaluated dose regimens included lapatinib (500-1500 mg/day), docetaxel (triweekly; 60-100 mg/m²), and trastuzumab (weekly; 2 mg/kg fixed dose); prophylactic granulocyte colony-stimulating factor was included with regimens with ≥750 mg/day lapatinib. End points included OTR and safety/tolerability (primary), overall response rate (ORR), and pharmacokinetics (secondary). RESULTS None of the patients (N = 53) experienced dose-limiting toxic effects (DLTs) at the highest dose level; thus, the OTR of lapatinib with 100 mg/m(2) docetaxel was not determined. Common adverse events included diarrhea, nausea, alopecia, fatigue, and rash; grade 3/4 (≥2 patients) were neutropenia, diarrhea, leukopenia, peripheral neuropathy, and rash. Seven patients had DLTs (cycle 1). In 45 patients with measurable disease confirmed by bone scan, investigator-assessed ORR was 31%; without bone scan, confirmation was 64%; 8 patients without measurable disease were evaluated as stable. Lapatinib/docetaxel plasma concentrations were positively associated with complete response. CONCLUSIONS Lapatinib/docetaxel/trastuzumab is a feasible and well-tolerated treatment of untreated HER2-positive stage IV MBC. Two lapatinib/docetaxel OTR doses were recommended (1250 mg/75 mg/m²; 1000 mg/100 mg/m²). CLINICAL TRIAL NUMBER NCT00251433.
Collapse
Affiliation(s)
- J Crown
- All Ireland Cooperative Oncology Research Group, Dublin, Ireland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014; 25:808-815. [PMID: 24615500 PMCID: PMC3969554 DOI: 10.1093/annonc/mdu009] [Citation(s) in RCA: 107] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 11/08/2013] [Accepted: 12/04/2013] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report on the incidence, time course, severity, and resolution of treatment-emergent adverse events (AEs) as well as incidence of dose modifications during the extended follow-up of this study. PATIENTS AND METHODS Patients were randomized (2:1) to receive EVE 10 mg/day or placebo (PBO), with open-label EXE 25 mg/day (n = 724). The primary end point was progression-free survival. Secondary end points included overall survival, objective response rate, and safety. Safety evaluations included recording of AEs, laboratory values, dose interruptions/adjustments, and study drug discontinuations. RESULTS The safety population comprised 720 patients (EVE + EXE, 482; PBO + EXE, 238). The median follow-up was 18 months. Class-effect toxicities, including stomatitis, pneumonitis, and hyperglycemia, were generally of mild or moderate severity and occurred relatively early after treatment initiation (except pneumonitis); incidence tapered off thereafter. EVE dose reduction and interruption (360 and 705 events, respectively) required for AE management were independent of patient age. The median duration of dose interruption was 7 days. Discontinuation of both study drugs because of AEs was higher with EVE + EXE (9%) versus PBO + EXE (3%). CONCLUSIONS Most EVE-associated AEs occur soon after initiation of therapy, are typically of mild or moderate severity, and are generally manageable with dose reduction and interruption. Discontinuation due to toxicity was uncommon. Understanding the time course of class-effect AEs will help inform preventive and monitoring strategies as well as patient education. TRIAL REGISTRATION NUMBER NCT00863655.
Collapse
Affiliation(s)
- H S Rugo
- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, USA.
| | - K I Pritchard
- Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada
| | - M Gnant
- Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | - S Noguchi
- Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan
| | - M Piccart
- Institut Jules Bordet, Brussels, Belgium
| | - G Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston
| | - J Baselga
- Memorial Sloan-Kettering Cancer Center, New York
| | - A Perez
- Memorial Cancer Institute, Hollywood, USA
| | - M Geberth
- Praxisklinic am Rosengarten Mannheim, Schwerpunktpraxis für Gynaekologische Onkologie, Mannheim, Germany
| | - T Csoszi
- Department of Medical Oncology, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary
| | - E Chouinard
- Cambridge Memorial Hospital, Cambridge, Canada
| | | | - P Puttawibul
- Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
| | - J Eakle
- Florida Cancer Specialists, Ft Myers
| | - W Feng
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - H Bauly
- Novartis Pharma AG, Basel, Switzerland
| | - M El-Hashimy
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - T Taran
- Novartis Pharmaceuticals Corporation, East Hanover, USA
| | - H A Burris
- Sarah Cannon Research Institute, Nashville, USA
| |
Collapse
|
40
|
Yardley DA, Hainsworth JD, Hamilton E, Hart LL, Shastry M, Finney L, Burris HA. Abstract OT1-1-13: A phase II study with lead-in safety cohort of cabazitaxel plus lapatinib as therapy for patients with HER2-positive metastatic breast cancer (MBC) and intracranial metastases. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot1-1-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-targeted therapy has improved the progress of patients (pts) with HER2-positive breast cancer; however, CNS metastases remain a significant source of morbidity and mortality. It is hypothesized that the inability of drugs like trastuzumab to cross the intact blood-brain barrier (BBB) may render the CNS as a sanctuary site for metastases. Lapatinib is an oral small molecule tyrosine kinase EGFR1/HER2 inhibitor that crosses the BBB and has activity against CNS metastases. Cabazitaxel is a new taxoid that is active in docetaxel- or paclitaxel-resistant breast cancer, and differs from other taxanes in its ability to cross the BBB. The promising systemic activity shown by cabazitaxel in taxane-resistant MBC coupled with the CNS penetrance of both cabazitaxel and lapatinib make this an attractive combination to evaluate in HER2-positive MBC pts with CNS metastases.
Study Objectives: The primary objectives of the study are to determine the safety and CNS objective response rate (ORR = CR+PR) in HER2-positive MBC pts with CNS metastases when treated with cabazitaxel and lapatinib. The secondary objectives include evaluation of the clinical benefit rate (CBR), 3- and 6-month PFS rate for CNS metastases, and response rate and CBR for extra-cranial metastases.
Key eligibility: Pts >18 yrs with HER2-positive (IHC 3+ or FISH/SISH-positive) MBC and unequivocal evidence of brain metastases are eligible. Additional eligibility criteria include: at least one measurable brain lesion >1.0cm in longest dimension on MRI; pts with brain lesions previously treated with WBRT and/or SRS must have at least one intra-cranial lesion >1.0cm not treated with SRS and must have evidence of intra-cranial progressive disease. Pts must have received at least 1 prior HER2-directed therapy in the adjuvant or metastatic setting; pts without prior chemotherapy for MBC are eligible if they progressed during or within 6 months of adjuvant therapy. Otherwise, there is no specific minimum or maximum number of previous chemotherapy regimens for MBC. ECOG performance status 0-2, adequate renal, bone marrow, and hepatic function are required; prior treatment with cabazitaxel or lapatinib (for MBC) not permitted.
Trial design: This is an open-label, non-randomized, phase II study with a lead-in safety cohort. During the lead-in phase, 6-15 pts will be treated in cohorts of 3 with increasing doses of cabazitaxel and lapatinib to determine the tolerability and optimal dose. Once the safety and dose is confirmed, subsequent pts will be treated at the optimal dose of the 2 agents. Each treatment cycle is 3 weeks and restaging will occur systemically and intra-cranially every 2 cycles for the first 8 cycles and every 3 cycles thereafter until progressive disease or unacceptable toxicity.
Statistical methods: We hypothesize that the addition of cabazitaxel will increase the CNS ORR from 6% (expected with single agent lapatinib) to ≥20% in this pt population. Treatment of 27 evaluable pts with the identified phase II doses will detect this difference with a power of 80% and alpha = 10% (one-sided test). Accounting for a 10% inevaluable rate and lead-in pts, a total of 45 pts will be enrolled on the study.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT1-1-13.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| | - JD Hainsworth
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| | - E Hamilton
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| | - LL Hart
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| | - M Shastry
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| | - L Finney
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| | - HA Burris
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL
| |
Collapse
|
41
|
Yardley DA, Burris HA, Chandra P, Liang S, Ma Z, Shastry M, Hainsworth JD. Abstract PD4-3: Use of community-based next-generation sequencing (NGS) in advanced breast cancer: Identification of actionable targets to guide clinical trial selection. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-pd4-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Molecularly targeted drugs specific for mutated genes are increasingly the focus of novel clinical trials. However, molecular profiling of tumors is largely unavailable in community cancer centers, where nearly 80% of cancer patients (pts) are treated. In October 2012, Sarah Cannon Research Institute (SCRI) launched a community-based molecular profiling initiative to characterize the spectrum of molecular alterations in tumors. The profiling panel focused on potentially actionable mutations for the purpose of identifying candidates for treatment with specific targeted agents (FDA approved or investigational). Herein, we report the initial data from breast cancers (BC) profiled between October 2012 and May 2013.
Methods: Metastatic breast cancer (MBC) pts > 18 years of age with ECOG PS ≤ 2 who were candidates for treatment provided consent for tumor molecular profiling. Archival tumor specimens (tissue block or 10 unstained slides) obtained from either the primary or metastatic disease were collected and interrogated by NGS (1000X average coverage) in a CLIA/CAP laboratory to detect oncogenic hotspot mutations in 35 cancer-related genes. Results were reported to the treating physician within 12 calendar days of receipt of suitable tissue and were stored in a database to enable correlation with clinical outcomes. Detection of relevant molecular abnormalities was used to identify pts appropriate for clinical trials of targeted agents.
Results: As of May 31 2013, a total of 594 tumor samples were profiled, 101 (17%) of which were BC samples. 8% (8/101) of the BC samples were inadequate for assay. Of the remaining 93 samples, 60 (65%) had no mutations detected. 28% of BC had single mutations and 7% had multiple mutations. PIK3CA mutations (24%) were the most frequently identified alteration. Other genetic alterations identified included RUNX1 (4%) and FGFR3 (2%) while mutations in PIK3R1, MET, KRAS, KIT, FGFR2, HER2, BRAF, SMO, MYC, DDR2 and AKT1 were infrequent, each identified in 1 pt. Patterns and frequency of mutations in the 35 genes assayed differed in the various subtypes of BC. 6% (6/93) of BC pts with appropriate tumor mutations identified by molecular profiling have been enrolled into phase I clinical trials with PI3K or mTORC1/2 inhibitors; updated treatment results will be presented. An additional 27 patients are potentially eligible for ongoing trials at SCRI.
Conclusions: This community-based molecular profiling initiative has been well accepted by patients and physicians, and provides timely results. Potentially actionable mutations were identified in 35% of BCs tested; PIK3CA mutations accounted for 70% of all actionable mutations detected. Identification of BC patients with actionable mutations may add to treatment options and improve results, and will also accelerate development of new targeted agents.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr PD4-3.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| | - HA Burris
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| | - P Chandra
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| | - S Liang
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| | - Z Ma
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| | - M Shastry
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| | - JD Hainsworth
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; PathGroup, Nashville, TN
| |
Collapse
|
42
|
Burris H, Gnant M, Hortobagyi G, Hart L, Yardley DA, Eakle J, Provencher L, Brechenmacher T, Saletan S, Taran T, Rugo H. Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-16-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, EVE, with the steroidal aromatase inhibitor, EXE, more than doubled median progression-free survival (PFS) compared with placebo (PBO) plus EXE in postmenopausal women with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) breast cancer (BC) who relapsed or progressed following a nonsteroidal aromatase inhibitor (NSAI). Patients also achieved responses per Response Evaluation Criteria in Solid Tumors (RECIST) during treatment with EVE+EXE.
Methods: The phase 3, double-blind, BOLERO-2 trial randomized postmenopausal women with HR+ BC progressing or recurring after NSAIs in a 2:1 manner to EVE 10 mg once daily plus EXE 25 mg once daily (EVE+EXE; n = 485) or placebo (PBO) plus EXE (PBO+EXE; n = 239). The primary endpoint was PFS by local assessment. Overall response rate (ORR; complete + partial response per investigator assessment based on RECIST 1.0) and duration of overall response were secondary endpoints. In addition, best percentage change from baseline in sum of longest diameters of target lesions was assessed.
Results: At the time of final PFS analyses at 18 months’ median follow-up, ORR was significantly higher in the EVE+EXE arm compared with the PBO+EXE arm (12.6% vs 1.7%, respectively, by local assessment; P<.0001). Among patients with measurable disease at baseline, 71% in the EVE+EXE arm had a decrease in the sum of longest diameters of target lesions compared with baseline vs 30% in the PBO+EXE arm. Median duration of overall response was 10.5 months (95% confidence interval [CI]: 8.2, 21.9 months) for EVE+EXE and 6.9 months (95% CI: 4.2, 6.9 months) for PBO+EXE. Of note, only 4 patients in the PBO+EXE arm had an objective response to treatment.
Conclusions: In addition to PFS, the combination of EVE plus EXE significantly improved ORR vs PBO+EXE in patients with HR+, HER2− advanced BC progressing during or after NSAI therapy. Furthermore, greater than two-thirds of patients treated with EVE+EXE experienced tumor shrinkage during treatment. These results further support the rationale for combining EVE with EXE to improve clinical outcomes in HR+, HER2− advanced BC progressing after NSAI therapy.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-17.
Collapse
Affiliation(s)
- H Burris
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - M Gnant
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - G Hortobagyi
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - L Hart
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - DA Yardley
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - J Eakle
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - L Provencher
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - T Brechenmacher
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - S Saletan
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - T Taran
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| | - H Rugo
- Sarah Cannon Research Institute; Comprehensive Cancer Center, Medical University of Vienna; The University of Texas MD Anderson Cancer Center; Florida Cancer Specialists; Centre des Maladies du Sein Deschênes-Fabia; Novartis Pharmaceuticals Corporation S.A.S; Novartis Pharmaceuticals Corporation; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF
| |
Collapse
|
43
|
Yardley DA, Barton J, Raefsky E, Harwin W, Priego V, Inclan A, Miletello G, Hart LL, Shastry M, Finney L, Hainsworth JD, Burris HA. Abstract P4-16-04: Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): Final results from a phase II trial of the Sarah Cannon Research Institute (SCRI). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-16-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anthracyclines are among the most effective agents in the treatment of breast cancer; however, dose-dependent cumulative cardiotoxicity limits their use. Amrubicin is a synthetic anthracycline topoisomerase II inhibitor demonstrating potent antitumor effects coupled with little potential for cardiotoxicity. We report the final results from a phase I/II trial of amrubicin as second- or third-line therapy for HER2-negative MBC.
Methods: Eligible patients (pts) included women with measurable HER2-negative MBC who had received 1 or 2 prior chemotherapy regimens for MBC. Previous anthracyclines were permitted if ≥ 6 months prior to study entry. Normal LVEF was required. Amrubicin 110 mg/m2 IV (dose established from phase I portion) was administered every 3 weeks until disease progression or intolerable toxicity; growth factor use was permitted. Disease evaluations were performed every 6 weeks and LVEF assessments every 12 weeks. Progression-free survival (PFS) was the primary endpoint; a median PFS ≥ 4.5 months would merit further evaluation of amrubicin in MBC. Toxicity, overall survival, and overall response rate (ORR) were secondary endpoints.
Results: Between 1/2010 and 3/2012, 78 pts were enrolled, and 66 pts are included in this analysis (ph I: 3 pts; ph II 63 pts). Baseline characteristics included: median age 59 years; hepatic metastases in 50%; ≥ 3 sites of metastatic disease in 32%. Triple-negative histology was noted in 27%; prior adjuvant chemotherapy in 50%; prior anthracyclines in 32%; and 2 prior cytotoxic regimens for MBC in 35%. Median treatment duration was 18 weeks (6 cycles), range 1- 24 cycles. The ORR was 21% in evaluable pts (2 CR, 10 PR); 5 of these 12 pts had prior anthracyclines. 14% were not evaluable. The clinical benefit rate (CBR) was 42% (CBR = CR+PR+SD≥ 4 months); 35% of these responders received ≥12 cycles of amrubicin. Median PFS for all pts was 4.0 months (95% CI 2.5- 5.8 months) and did not significantly differ by line of therapy administered (4.0 months as 2nd line vs 4.7 as 3rd line therapy). 36% of pts were free of progression at 6 months. Neutropenia was the most common grade 3/4 toxicity present in 42% and accompanied by fever in 7%. No grade 3/4 non-hematologic toxicity occurred in > 5% pts. One pt previously treated with anthracyclines experienced a transient 20% LVEF decline to 44% at cycle 4. This recovered to baseline within 2 weeks and pt continued to receive 2 additional cycles of amrubicin before experiencing PD. No other grade 3/4 cardiac events were noted. In 3 pts, amrubicin was discontinued due to toxicity (G4 neutropenia, G2 thrombocytopenia, G2 nausea/vomiting/vertigo).
Conclusions: Amrubicin was active and well tolerated in the second- or third-line MBC setting with manageable toxicity. The ORR of 21% and median PFS of 4 months are comparable to other single agents in this setting. The observed CBR of 42%, and the fact that nearly 1/3 of these responders received ≥12 cycles of amrubicin with no cardiotoxicity, suggests that future evaluations of amrubicin in breast cancer are warranted.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-16-04.
Collapse
Affiliation(s)
- DA Yardley
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - J Barton
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - E Raefsky
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - W Harwin
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - V Priego
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - A Inclan
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - G Miletello
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - LL Hart
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - M Shastry
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - L Finney
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - JD Hainsworth
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| | - HA Burris
- Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Center for Cancer and Blood Disorders, Bethesda, MD; Woodlands Medical Specialists, Pensacola, FL; Hematology/Oncology Clinic, LLP, Baton Rouge, LA
| |
Collapse
|
44
|
Yardley DA, Barton J, Dickson N, Shipley D, Drosick DR, Hendricks C, Inhorn RC, Shastry M, Finney L, Burris HA. Abstract P5-17-05: Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer: Preliminary Results of the Phase II Trial of the Sarah Cannon Research Institute. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-17-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sorafenib (S) is an oral multi-kinase inhibitor with effects on tumor proliferation and angiogenesis, targeting VEGFR1 and VEGFR2. It has modest activity as a single agent in breast cancer. In combination with capecitabine, S demonstrated a significant improvement of 2.3 months in progression free survival (PFS) in patients (pts) with metastatic breast cancer (MBC) and added benefit when combined with paclitaxel. Ixabepilone (Ixa) is a semi-synthetic analog of epothilone B with excellent single agent activity in MBC. The phase I portion of this trial identified the MTD of the Ixa and S combination. We now report the initial results of the phase II trial with this novel combination.
Methods: Eligibility criteria included: HER2-negative MBC previously untreated with chemotherapy; measurable disease; ECOG PS 0–2; normal LVEF; and adequate bone marrow and organ function. Prior hormonal therapy for MBC was permitted. Pts received Ixa 32mg/m2 IV on day 1 of each 21-day cycle and S 400mg PO BID. Following a minimum of 4 cycles of the combination, responding pts could discontinue Ixa and remain on study treatment with S monotherapy. Granulocyte-stimulating growth factors were permitted after cycle one. Tumor assessments were performed every 9 weeks. Pts continued study treatment until disease progression or unacceptable toxicity. The primary endpoint of this trial was PFS; the addition of S to Ixa was hypothesized to improve PFS from 4.2 month to 6.2 months in this patient population. The total enrollment goal is 85 pts, and the trial is currently open to accrual.
Results: Between 5/2010 and 4/2012, 76 pts have been enrolled, and 57 pts (56 females, 1 male) are included in this analysis. Baseline characteristics included: median age 58; 61% were ER and/or PR positive; 39% were triple-negative; 39% received neoadjuvant therapy. Anthracycline exposure was noted in 34 pts and prior taxane exposure in 39 pts. 29 pts received prior hormonal therapy, 7 of these for MBC. Sites of metastatic disease included lymph nodes 42%, lung 35%, liver 30%, bone 30%, and 23% other. 19 pts (33%) had 3 or more sites of metastatic disease. Median treatment duration was 3 cycles (9 weeks), range 1–11+ cycles with 9 pts discontinuing Ixa after a median of 6 cycles and continuing on S monotherapy. 12 pts (21%) had objective responses (1 CR, 11 PR); 3 of the 22 (14%) triple-negative patients had responses (1 CR, 2 PR). An additional 24 patients (42%) had stable disease at first reevaluation. Neutropenia was the most common grade 3/4 toxicity (26%) with growth factor use reported in 35%. Grade 3/4 non-hematologic toxicity occurring in > 5% of patients consisted of: rash (12%), fatigue (11%), hypersensitivity reaction (7%, Ixa= 3 pts and S= 1 pt), and neuropathy (7%). Discontinuation due to adverse events occurred in 11%.
Conclusion: The combination of Ixa and full dose S was well tolerated with no new observed toxicities. Adverse events were manageable and consisted primarily of G3/4 neutropenia and rash. Study is ongoing and updated results will be presented.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-17-05.
Collapse
Affiliation(s)
- DA Yardley
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - J Barton
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - N Dickson
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - D Shipley
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - DR Drosick
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - C Hendricks
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - RC Inhorn
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - M Shastry
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - L Finney
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| | - HA Burris
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME
| |
Collapse
|
45
|
Yardley DA, Hainsworth JD, Shastry M, Finney L, Burris HA. Abstract OT3-3-08: Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-ot3-3-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy for locally advanced breast cancer improves survival and rates of breast-conserving surgery. Pathologic complete response (pCR) after neoadjuvant therapy strongly correlates with improved disease free survival (DFS) and provides an early indicator of treatment efficacy. The expected pCR rate with a standard taxane-containing combination is approximately 18%. Eribulin is a non-taxane synthetic analogue of halichondrin B that inhibits microtubule dynamics by a novel mechanism of action distinct from other tubulin-targeting agents. Eribulin is active against taxane and anthracycline pretreated metastatic breast cancer (MBC) and is well tolerated with a predictable toxicity profile. Substitution of eribulin for docetaxel in a neoadjuvant combination regimen may therefore improve efficacy. This study will evaluate the non-anthracycline eribulin/cyclophosphamide (ErC) and docetaxel/cyclophosphamide (TC) combinations as neoadjuvant therapy. The first ten patients (pts) will be evaluated for tolerability and feasibility of standard prescribed eribulin monotherapy dosing in combination with standard dose cyclophosphamide.
Study Objectives: This randomized phase II trial is designed to determine the pCR rate of locally advanced, HER2-negative breast cancer treated with 6 cycles of ErC or TC. The secondary objectives are to evaluate the clinical response rate of ErC as neoadjuvant therapy and to determine the 2 year DFS of pts treated with ErC and TC.
Eligibility: Females ≥ 18 years with untreated, locally advanced, HER2-negative breast cancer appropriate for neoadjuvant chemotherapy are eligible. Eligibility criteria include: adenocarcinoma histology; clinical T1-3, N0-2, M0 breast tumors; ECOG PS 0–2; known hormone receptor status at study entry; adequate bone marrow and organ function; willingness to provide archived biopsy specimen for correlative testing. Clinical N3, T1N0M0, and T4 tumors are excluded. Upfront axillary lymph node sampling and/or definitive nodal surgery is permitted, and demonstrated pN3a disease is allowed.
Trial Design: A lead-in phase of the trial will enroll 10 pts to be treated with ErC to determine safety and feasibility of the combination. If the safety is confirmed, subsequent pts will be stratified by hormone receptor status (positive vs. triple- negative) and will be randomized in a 2:1 ratio to Arm 1: ErC or Arm 2: TC. Pts on Arm 1 will receive eribulin 1.4 mg/m2 IV (Days 1 & 8) and cyclophosphamide 600 mg/m2 IV (Day 1). Pts on Arm 2 will receive docetaxel 75 mg/m2 IV (Day 1) and cyclophosphamide 600 mg/m2 IV (Day 1). Both regimens are repeated every 21 days for a total of 6 cycles. After completion of neoadjuvant chemotherapy, pts will undergo definitive local surgery, as determined by the treating surgeon. Archival tumor samples and residual tumor tissue at surgery will be collected for biomarker evaluations. A total of 66 pts (Arm 1: 44; Arm 2: 22) will be enrolled to this study. A pCR rate ≥ 18% in patients treated with ErC is considered a study result that merits further evaluation. This trial is pending activation and has a total accrual goal of 76 pts.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT3-3-08.
Collapse
Affiliation(s)
- DA Yardley
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - JD Hainsworth
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - M Shastry
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - L Finney
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - HA Burris
- Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
46
|
Bendell J, Weiss G, Infante J, Ramanathan R, Jones S, Korn R, Burris H, Brail L, Jones E, Von Hoff D. 594 A Phase I Dose-escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of LY2940680, an Oral Smo Inhibitor. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72391-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Burris H, Hart L, Kurkjian C, Berk G, Lipman P, Patel C, Rommel C, Martin M, Infante J. 605 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72402-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
48
|
Burris H, Beck J, Rugo H, Baselga J, Lebrun F, Taran T, Bennett L, Ricci J, Sahmoud T, Hortobagyi G. Health-Related Quality of Life (QOL) in Metastatic Breast Cancer Patients Treated With Everolimus and Exemestane Versus Exemestane Monotherapy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32894-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
49
|
Yardley DA, Peacock NW, Peyton J, Shipley DL, Spigel S, Barton J, Shih KC, Raefsky E, Liggett W, Burris HA, Hainsworth JD. P3-14-29: Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-14-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Angiogenesis plays a substantial role in breast cancer development as well as in triple negative breast cancer (TNBC). Sunitinib is an inhibitor of the tyrosine kinase receptors for VEGF, platelet-derived growth factor (PDGF), KIT, RET, and fms-like tyrosine kinase receptor-3 (FLT3). As monotherapy in heavily pretreated breast cancer patients (pts), sunitinib demonstrated a response rate of 15% in TNBC (11% of all pts) with stable disease or better in 16% of all pts. The combination of paclitaxel and carboplatin is ideally suited for further exploration as neoadjuvant chemotherapy for TNBC, based on the established preclinical and clinical sensitivity of TNBC to these cytotoxic agents. This open label, phase I/II trial was designed to evaluate the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer. The primary objective for the phase I portion was to determine the maximum tolerated dose (MTD); these results are presented. Methods: Women with histologically confirmed invasive triple-negative adenocarcinoma of the breast, (defined as <10% staining by IHC for ER/PR; IHC 0–1+ or FISH negative for HER2), with no evidence of metastatic disease and normal LVEF were eligible. All pts received sunitinib (days 1–28), paclitaxel (days 1, 8, 15), and carboplatin (day 1) in 28-day treatment cycles x6. Following 6 cycles, pts had definitive surgery. After ≥2 weeks and evidence of adequate wound healing, maintenance sunitinib 25mg PO daily was initiated to complete a total of 52 weeks. Three dose levels were evaluated as shown in the table below:
Doses were escalated in sequential cohorts of pts using standard phase I methodology. MTD was defined as the highest dose level (DL) producing ≤1 dose limiting toxicities (DLTs) in a pt cohort. The MTD identified in the phase I portion of the study will be used in the phase II portion, which will evaluate the efficacy, safety, and tolerability of this combination in pts with locally advanced TNBC.
Results: 15 women with TNBC were enrolled between 10/2009 and 2/2011 [median age 53 years (range: 40–78)]. Due to grade 3 neutropenia resulting in the inability to deliver cycle 1 day 15 paclitaxel in the first pt treated at both DLs 1 and 2, these DLs were expanded to 6 pts each. No additional cycle 1 DLTs were noted in the 5 additional pts at either DL. Three pts were accrued to DL 3; there were 2 DLTs noted among these pts (grade 3 febrile neutropenia; grade 3 neutropenia with cycle 2 day 1 treatment delay). However, due to the development of grade 3/4 neutropenia in subsequent cycles in 5 of 6 DL 2 pts, resulting in dose delays and requiring dose reductions, the MTD of this combination was defined as DL 1 (paclitaxel 70mg/m2 (Days 1, 8, 15); carboplatin AUC=5 (Day 1); sunitinib 25mg PO daily).
Conclusions: The administration of sunitinib with paclitaxel plus carboplatin as neoadjuvant therapy is feasible with neutropenia defining the MTD of this combination. The phase II portion of this study is ongoing.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-14-29.
Collapse
Affiliation(s)
- DA Yardley
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - NW Peacock
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - J Peyton
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - DL Shipley
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - S Spigel
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - J Barton
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - KC Shih
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - E Raefsky
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - W Liggett
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - HA Burris
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| | - JD Hainsworth
- 1Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN
| |
Collapse
|
50
|
Tolaney S, Burris H, Gartner E, Mayer I, Saura C, Maurer M, DeCillis A, Ruiz-Soto R, Lager J, Winer E, Krop I. P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-17-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Most HER2+ MBC patients (pts) treated with a combination of T+P progress within 1 year. Activation of downstream pathways through either deficiency in PTEN or mutations in the PI3K pathway has been implicated in the development of resistance to T. S08 is a potent, orally bioavailable, pan-PI3K inhibitor that inhibits phosphorylation of multiple downstream components of the PI3K/PTEN signaling pathway and has demonstrated activity as a single agent and in combination with other anticancer agents (Edelman G, et al., ASCO 2010; Traynor AM, et al. ASCO 2010).
PATIENTS and METHODS: This ongoing, open-label multicenter phase 1/2 study (NCT01042925) was designed to assess safety and tolerability of S08 in combination with either T or T+P. Eligible female pts were ≥18 yrs, ECOG PS 0–2, with adequate organ and marrow function and had advanced or recurrent HER2+ MBC disease refractory to T. Pts have received, and progressed on at least 1 prior T-containing regimen for metastatic disease. Pts were allocated to Arm 1 or Arm 2 and received different dose levels of S08 (starting dose 200 mg PO, daily) in combination with either T 8/6 mg/kg IV on Day (D) 1 q3w (Arm 1) or T 8/6 mg/kg IV on D1 + P 80 mg/m2 on D 1, 8, and 15 q3w (Arm 2). In phase 1, a standard ascending 3 + 3 dose escalation design was used in each arm to evaluate safety/tolerability of the combinations. Following establishment of preliminary maximal tolerated doses (MTDs) for each combination, subsequent pts will be accrued to the phase 2 portion. Approximately 25 additional pts will be enrolled in each arm to further evaluate the safety and estimate the overall response rate (ORR) in each arm.
RESULTS: As of June 1st 2011, 33 pts median age 55 yrs were enrolled; 18 to Arm 1 and 15 to Arm 2. Based on preliminary data of the study, in Arm 1, the most common treatment emergent adverse events (TEAEs) regardless of relationship include rash, diarrhea, fatigue, nausea, vomiting; in Arm 2 were neutropenia, diarrhea, fatigue, nausea, hyporexia, hypokalemia, peripheral neuropathy, rash and hyperglycemia. SAEs reported in Arm 1 (3 subjects) included Gr3 dehydration (2 cases), Gr3 epigastric pain and Gr2 dyspnea; those SAEs in Arm 2 (4 subjects) included Gr4 neutropenia, Gr3 anorexia, Gr3 dehydration, Gr3 epigastric pain, Gr3 thromboembolism, Gr2 nausea, Gr2 pneumonitis and Gr2 headache. A total of 4 DLTs were reported; 2 in Arm 1 [Gr3 skin rash (S08; 400 mg dose)] and 2 in Arm 2 [Gr4 neutropenia (S08; 200mg dose)] (table 1). With phase I nearly complete, the MTD for arm 1 is S08 300 mg PO daily and T 8/6 mg/kg D1 q3w. The data for Arm 2 (current dose level ongoing at the maximum allowed per protocol) will be completed in August 2011. Preliminary PK data did not show interactions between S08 and either T or T+P.
DISCUSSION: S08 can be combined with either T or with T+P.
Additional safety, PK and efficacy data will be presented from phase 1.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-17-02.
Collapse
Affiliation(s)
- S Tolaney
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - H Burris
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - E Gartner
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - I Mayer
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - C Saura
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - M Maurer
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - A DeCillis
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - R Ruiz-Soto
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - J Lager
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - E Winer
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| | - I Krop
- 1Dana Farber Cancer Insitute, Boston, MA; Sarah Canon Research Center, Nashville, TN; Wayne State University/Karmanos Cancer Institute Hematology/Oncology, Detroit, MI; Vanderbilt Ingram Cancer Center, Nashville, TN; Vall d'Hebron University Hospital, Barcelona, Spain; Columbia University Medical Center, New York, NY; Exelixis, San Francisco, CA; Sanofi, Cambridge, MA
| |
Collapse
|